EULAR 2013 Congress Madrid - Preliminary Scientific Programme

Please note that this is a Preliminary Version of the Scientific Programme for the EULAR Congress 2013 in Madrid. The programme is subject to change at any time.

Details on Oral Abstract Presentations will be published by approximately one month prior to the congress. Until then, you will see the lecture slot, but without presenter name and without abstract title.

To select single time slots, please use the drop down selection option (Standard: Overview all days and sessions).

To print, please use the 'File - Print' option of your browser. Best results are achieved using landscape and scaling down to 70 percent in the printer preferences.

Overview

Wednesday 12.06.2013 13:30 - 14:30

Health Professionals Session - Room N113/114

Looking forward to EULAR Madrid 2013

Chair: Corneliu Patria (United Kingdom)

Speaker: Corneliu Patria (United Kingdom) SP0001 Finding your way around EULAR – hot tips for a successful conference

Speaker: Citiolo Maurizio (Italy) The opportunities of the Health Professional in EULAR – the new president’s perspective

PARE Session - Room N116

Pre-conference outlook for PARE delegates

Chair: Batziou Maria (Greece)

Speaker: Batziou Maria (Greece) General information, logistics and outlook on EULAR 2013

Wednesday 12.06.2013 15:00 - 16:30

What is New (WIN) - Hall 6

WIN Session 1

Speaker: Gabay Cern (Switzerland) SP0002 Therapy of rheumatoid arthritis

Speaker: Lories Rik (Belgium) SP0003 Spondyloarthritis

Clinical Science Session - Hall 8

Psoriatic arthritis - new outcomes and therapy options

Chair: Gladman Dahna D. (Canada)

Chair: Porssen Inge Juul (Denmark)

Speaker: FitzGerald Oliver (Ireland) SP0004 How to assess disease activity and severity in clinical practice

Speaker: Helliwell Philip (United Kingdom) SP0005 Is it time to aim for remission in PsA and how should it be measured?

Speaker: Mease Philip (United States) New therapies in PsA

Abstract: Ritchin C (United States) OP0001 MAINTENANCE OF EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS DESPITE PRIOR CONVENTIONAL NONBIOLOGIC AND ANTI-TNF BIOLOGIC THERAPY: 1 YR RESULTS OF THE PSUMMIT 2 TRIAL

Speaker: Gilbert John J (United Kingdom) SP0006 To what extent can genomics improve PsA care?
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Kavanaugh Arthur (United States)</th>
<th>LB0001</th>
<th>LONG-TERM (52-WEEK) RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS</th>
</tr>
</thead>
</table>

**How to Treat / Manage (HOT) - Hall 7**

**HOT Session 1**

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Bijtsma Johannes W.J. (Netherlands)</th>
<th>Osteoarthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker</td>
<td>Doria Andrea (Italy)</td>
<td>Systemic lupus erythematosus SLE</td>
</tr>
</tbody>
</table>

**Clinical Science Session - Room N103/104**

**Chronic gout: imaging, diagnosis, treatment**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Isaacs John D. (United Kingdom)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Hermann Walter (Germany)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Manger Bernhard (Germany)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Kay Jonathan (United States)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Pillinger Michael (United States)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Kee Seung-Jung (Korea, Republic Of)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Scirè Carlo Alberto (Italy)</td>
</tr>
</tbody>
</table>

**Challenges in Clinical Practice Session - Hall 4**

**Osteonecrosis and rheumatic diseases**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Kraenzlin Marius (Switzerland)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Anaya Juan Manuel (Colombia)</td>
</tr>
<tr>
<td>Presenter</td>
<td>Spies Cornelia (Germany)</td>
</tr>
<tr>
<td>Discussant</td>
<td>Kraenzlin Marius (Switzerland)</td>
</tr>
<tr>
<td>Presenter</td>
<td>Spies Cornelia (Germany)</td>
</tr>
<tr>
<td>Discussant</td>
<td>Kurth Andreas (Germany)</td>
</tr>
</tbody>
</table>

**Outcomes Science Session - Room N101/102**

**Cardiovascular risk in inflammatory arthritis**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Nurmohamed Michael (Netherlands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Scirè Carlo Alberto (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Hinty Mark (United States)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Andrews Jacqueline (United Kingdom)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Harris Helen (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Meek Inger (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Pappas D (United States)</td>
</tr>
</tbody>
</table>

**PReS Session - Room N105/106**
Mechanisms and treatment of autoinflammatory diseases

Chair: Anton Jordi (Spain)

Speaker: Mantovani Alberto (Italy)

Speaker: Remmers Elaine (United States)

Speaker: Galtorno Marco (Italy)

Abstract: Wipf Julius (France)

Clinical Science Session - Room Retiro

EULAR / ESSR Session: What is next in imaging in rheumatology: the radiologists’ perspective

Chair: Schueller-Weidekamm Claudia (Austria)

Chair: Ostergaard Mikkel (Denmark)

Speaker: Jurik Anne Grethe (Denmark)

Speaker: Roemer Frank (United States)

Speaker: Hermann Kay-Geert (Germany)

Abstract: Wipf Julius (France)

B cells in auto-immune response: how do they look and what do they need?

Chair: Mei Henrik (United States)

Chair: Chang Hyun-Dong (Germany)

Speaker: Malmsiström Vivianne (Sweden)

Speaker: Mariette Xavier (France)

Speaker: Mei Henrik (United States)

Abstract: Dagens Claire (France)

Abstract: Toussirot Eric (France)

Basic and Translational Science Session - Room N107/108

Complementopathies – new mechanisms for old diseases

Chair: Perricone Roberto (Italy)

Speaker: Rodriguez de Cordoba Santiago (Spain)

Speaker: Salmon Jane E. (United States)

Speaker: Pickering Matthew (United Kingdom)

Abstract: Chauhan Anil (United States)

Educational Session - Room N111/112

EULAR Scientific Training Bursary Winners

<table>
<thead>
<tr>
<th>Chair</th>
<th>Lundberg Ingrid (Sweden)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Mandl Peter (Austria)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Dadoun Sabrina (France)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Nerviani Alessandra (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Pambili Cristina (Romania)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Sciascia Savino (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Janta Justina (Romania)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Vieju Florin (Romania)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Santiago Tanis (Portugal)</td>
</tr>
</tbody>
</table>

- **Health Professionals Session - Room N113/114**

  - **Sustaining the working lives of people with arthritis**

    | Chair | Kerandova Jana (Czech Republic) |
    |-------|-------------------------------|
    | Chair | Wooll Anthony (United Kingdom) |
    | Speaker | Bieleman Hendrik J. (Netherlands) |
    | Speaker | Willie Ross (United Kingdom) |
    | Speaker | Hubertsson Jenny (Sweden) |
    | Abstract | Björk Mathilda (Sweden) |
    | Speaker |until old age |
    | Speaker | Healthy work life expectancy in older adults with arthritis; how long can people with arthritis work for and what maintains work participation until old age |
    | Speaker | Sick leave and disability pension in working age women and men with knee osteoarthritis |
    | Abstract | Reduced sick leave in today’st early RA patients compared to 10 years ago, the Swedish TiRA project |

  - **Practical Skills Session - Room N117**

    - **Ultrasound Basic 1**

      | Chair | Uson Jacqueline (Spain) |
      |-------|--------------------------|
      | Speaker | Kane David (Ireland) |
      | Speaker | Möller Ingrid (Spain) |
      | Speaker | Dejaco Christian (Austria) |
      | Speaker | Schmidt Wolfgang A. (Germany) |
      | Abstract | How to distinguish normal from abnormal findings |
      | Speaker | How does anatomy help to learn ultrasound? |
      | Speaker | The practical case: is it really easy to distinguish gout from CPPD by ultrasound? Live case with patient |
      | Speaker | Hands-on scanning in groups with patients with gout and CPPD |

  - **Practical Skills Session - Room N118**

    - **Laboratory Course 1**

      | Chair | Bürmester Gerd Rödiger (Germany) |
      |-------|-------------------------------|
      | Chair | Dörner Thomas (Germany) |
      | Speaker | Wilk Allan (Denmark) |
      | Speaker | Dörner Thomas (Germany) |
      | Speaker | Miossec Pierre (France) |
      | Speaker | Dörner Thomas (Germany) |
      | Speaker | Anti-citrullinated peptide antibodies and neutrophil-specific antibodies |
      | Speaker | Current aspects of ANA and antiphospholipid antibody detection |
      | Speaker | Cytokine detection: methods & interpretation |
      | Speaker | Q&A and discussion |

  - **Practical Skills Session - Room N115**

    - **Crystals in synovial fluid**

The 5 year course of physical work capacity in people with early OA: a longitudinal study in the CHECK cohort

How does anatomy help to learn ultrasound?

The practical case: is it really easy to distinguish gout from CPPD by ultrasound? Live case with patient

Idenfication of morphological and mechanical changes in soft tissue in systemic sclerosis

Reduced sick leave in today’s early RA patients compared to 10 years ago, the Swedish TiRA project
PARE Session - Room N116

Political campaigning
Chair Betteridge Neil (United Kingdom)
Chair Koutsogianni Katerina (Greece)
Speaker Teutriene Bjorn (Germany) SP0019 The German action plan for young people with RMDs
Speaker Smolen Josef S. (Austria) SP0020 Lobbying on “Horizon 2020” – an illustration how campaigning at the national and EU levels simultaneously can make a positive difference to the lives of people with RMDs
Speaker Åkesson Kristina (Sweden) SP0021 Working together to make rheumatic and musculoskeletal conditions a public health priority - gaining strength through the global Bone and Joint Decade alliance
Abstract Mali Souzi (Cyprus) OP0011-PARE ON THE ROAD TO RAISING AWARENESS AND EMPOWERING PATIENTS.
Abstract Holch Jacob (Denmark) OP0012-PARE USING SOCIAL COSTS OF MSDS AS A SELLING POINT TO POLITICIANS

Wednesday 12.06.2013 17:00 - 18:30
Clinical Science Session - Hall 8

Can we prevent RA? Disease mechanisms, risk factors and therapeutic approaches
Chair van Schaardenburg Dirkjan (Netherlands)
Speaker Rantapää Dahlqvist Solbrit (Sweden) SP0020 Risk factors for RA: gene environment interactions
Speaker Catrina Arca (Sweden) SP0021 The onset of RA: disease processes at extraarticular sites
Speaker Gerlag Daniëlle (Netherlands) SP0022 Prevention is better than cure: a new dawn for the management of RA?
Speaker Raza Karim (United Kingdom) SP0023 Recommendations for reporting in clinical studies of the earliest phases of RA: the EULAR Study Group for Risk Factors for RA
Abstract Yeo Lorraine (United Kingdom) OP0013 A NOVEL PRO-INFLAMMATORY B CELL POPULATION INFILTRATING THE RHEUMATOID SYNOVIUM CAN BE IDENTIFIED BY EXPRESSION OF FCRL4

How to Treat / Manage (HOT) - Hall 7

HOT Session 2
Speaker Askling Johan (Sweden) SP0024 Comorbidty in rheumatic diseases
Speaker Schmidt Wolfgang A. (Germany) SP0025 Localised rheumatic syndromes

Clinical Science Session - Room N103/104

Imaging of the cartilage
Chair Uson Jacqueline (Spain)
Chair Möller Ingrid (Spain)
**Challenges in Clinical Practice Session - Hall 4**

**Low Back Pain: from specific lesions to personalised treatment**

- **Chair**: Genevay Stéphane (Switzerland)
- **Chair**: Rannou François (France)
- **Presenter**: Nguyen Christelle (France) - Case 1 presentation: Low back pain and modic lesion
- **Discussant**: Rannou François (France) - Case 1 discussion: The concept of active discolysis
- **Presenter**: Fleury Gregory (Switzerland) - Case 2 presentation: Back Pain: discs, facets, S-I joints, .... what else?
- **Discussant**: Genevay Stéphane (Switzerland) - Case 2 discussion: Back Pain: discs, facets, S-I joints, .... what else?

**Outcomes Science Session - Room N101/102**

**Translation gaps in Outcomes Science**

- **Chair**: Bombardier Claire (Canada)
- **Chair**: Myasoedova Elena (United States)
- **Speaker**: van der Heijde Désirée (Netherlands) - Characteristics of a good recommendation
- **Speaker**: Smolen Josef S. (Austria) - Barriers to implementation of recommendations
- **Abstract**: Shaw Yornei (United States) - OP0016 THE INFLUENCE OF PATIENT AND PHYSICIAN FACTORS ON DECISIONS TO ADJUST THERAPY FOR RHEUMATOID ARTHRITIS PATIENTS IN MODERATE TO HIGH DISEASE ACTIVITY
- **Speaker**: Bombardier Claire (Canada) - SP0028 Are guidelines really changing outcomes?

**PReS Session - Room N105/106**

**Pathogenetic insights in autoimmunity from genetic diseases**

- **Chair**: Wulfraat Nico (Netherlands)
- **Chair**: Martinl Alberto (Italy)
- **Speaker**: Cheng Mickie (United States) - Monogenic autoimmune diseases
- **Speaker**: Fischer Alain (France) - Autoimmunity in immunodeficiencies
- **Speaker**: Rönnblom Lars (Sweden) - Type I Interferonopathies
- **Abstract**: Cron Randy (United States) - OP0017 BLURRING OF THE DISTINCTION BETWEEN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND MACROPHAGE ACTIVATION SYNDROME

**Clinical Science Session - Room Retiro**

**The burden of Rheumatic Musculoskeletal Diseases RMDs**

- **Chair**: Dougdos Maxime (France)
<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betteridge Neil</td>
<td>Lirussi Flavio (Italy)</td>
<td>Musculoskeletal diseases and the WHO</td>
</tr>
<tr>
<td>March Lyn (Australia)</td>
<td>Carmona Loreto (Spain)</td>
<td>The Lancet publication</td>
</tr>
</tbody>
</table>

### Basic and Translational Science Session - Room N107/108

#### Can we treat OA as an inflammatory disease?

<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Högle Thomas</td>
<td>Pap Thomas (Germany)</td>
<td>Synovial pannus formation, does it exist in OA?</td>
</tr>
<tr>
<td>Noori-van der Laan Willemiijn</td>
<td>Walsh David (United Kingdom)</td>
<td>Angiogenesis in synovial inflammation differences between OA and RA</td>
</tr>
<tr>
<td>Klepperenburg Margaret (Netherlands)</td>
<td>Chevalier Xavier (France)</td>
<td>Inflammation in OA versus RA: a clinical perspective</td>
</tr>
</tbody>
</table>

#### Genetics and beyond

<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worthington Jane</td>
<td>Kureeeman Fina (Netherlands)</td>
<td>Genetic markers in RA, what do they mean and what can they do?</td>
</tr>
<tr>
<td>Goulielmos George</td>
<td>Kollias George (Greece)</td>
<td>Functional genetics; the insight obtained from animal models</td>
</tr>
<tr>
<td>Martin Javier (Spain)</td>
<td>Chevalier Xavier (France)</td>
<td>The genetics of scleroderma</td>
</tr>
</tbody>
</table>

### Basic and Translational Science Session - Room N109/110

#### Genetics and beyond

<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worthington Jane</td>
<td>Kureeeman Fina (Netherlands)</td>
<td>Genetic markers in RA, what do they mean and what can they do?</td>
</tr>
<tr>
<td>Martín Javier</td>
<td>Kollias George (Greece)</td>
<td>Functional genetics; the insight obtained from animal models</td>
</tr>
<tr>
<td>Lessard Christopher</td>
<td>De Rooy Diedenrik (Netherlands)</td>
<td>Identification of multiple Sjögren's Syndrome susceptibility loci</td>
</tr>
</tbody>
</table>

### Educational Session - Room N111/112

#### Rheumatology training in Europe

<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lundberg Ingrid</td>
<td>Sivera Francisca (Spain)</td>
<td>Rheumatology training in Europe: an overview</td>
</tr>
<tr>
<td>Ramiro Sofia</td>
<td>Ramiro Sofia (Portugal)</td>
<td>Project: Assessing the standard of rheumatology training for fellows across Europe</td>
</tr>
<tr>
<td>Chatzidionysou Katerina (Sweden)</td>
<td>Chevalier Xavier (France)</td>
<td>Personal experience</td>
</tr>
<tr>
<td>Michels-van Amelstorf J.M.R (Netherlands)</td>
<td>Lundberg Ingrid (Sweden)</td>
<td>Personal experience</td>
</tr>
</tbody>
</table>

### Health Professionals Session - Room N113/114
### Web-based technologies to support patients with rheumatic diseases

<table>
<thead>
<tr>
<th>Chair</th>
<th>Taal Erik (Netherlands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Molloy Miriam (Ireland)</td>
</tr>
<tr>
<td>Speaker</td>
<td>van der Vaart Roos (Netherlands)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Newman Stanton (United Kingdom)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Stinson Jennifer (Canada)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Nata Ingrid (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Revenäs Åsa (Sweden)</td>
</tr>
</tbody>
</table>

**Development and evaluation of a hospital webportal with access to an electronic health record for rheumatology patients**

**Evaluation of a web-based information and advice tool for parents of children with newly diagnosed JIA**

**A web-based self-management program for adolescents with arthritis**

**Development and evaluation of a web-based patient decision aid to support arthritis patients with making decisions about medication.**

### Practical Skills Session - Room N117

#### MRI Basic 1

<table>
<thead>
<tr>
<th>Chair</th>
<th>Hermann Kay-Geert (Germany)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Ostergaard Mikkel (Denmark)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Ostergaard Mikkel (Denmark)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Schueler-Weidekamm Claudia (Austria)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Hermann Kay-Geert (Germany)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Conaghan Philip (United Kingdom)</td>
</tr>
</tbody>
</table>

**Diagnosis of RA and SpA using MRI**

**Pitfalls in MRI in peripheral and inflammatory arthritis**

**MRI in psoriatic arthritis – from spine to toes**

**Case presentations: interaction and discussion**

### Practical Skills Session - Room N118

#### Diagnostic and prognostic use of capillaroscopy in rheumatology 1

<table>
<thead>
<tr>
<th>Chair</th>
<th>Cutolo Maurizio (Italy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Herrick Ariane L. (United Kingdom)</td>
</tr>
<tr>
<td>Chair</td>
<td>Smith Vanessa (Belgium)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Herrick Ariane L. (United Kingdom)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Hermann Walter (Germany)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Smith Vanessa (Belgium)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Sulli Alberto (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Cutolo Maurizio (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Herrick Ariane L. (United Kingdom)</td>
</tr>
</tbody>
</table>

**Raynaud's phenomenon: a clinical symptom that must be diagnosed by capillaroscopy**

**Selecting the most appropriate capillaroscopic device: pros and cons**

**How to distinguish normal from pathological capillaroscopic patterns**

**How to score the qualitative capillaroscopic patterns in systemic sclerosis**

**The prognostic value of the capillaroscopic analysis**

**Practical session with videocapillaroscopy in living patients and general discussion**

### Practical Skills Session - Room N115

#### Improving your graphs for publications

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Boers Maarten (Netherlands)</th>
</tr>
</thead>
</table>

**Improving your graphs for publication and presentation**

### Joint Clinical / HPR / PARE Session - Room N116

#### Healthy ageing

<table>
<thead>
<tr>
<th>Chair</th>
<th>Poor Gyula (Hungary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Põldemaa Ingrid (Estonia)</td>
</tr>
</tbody>
</table>
Thursday 13.06.2013 08:15 - 09:45

Basic and Translational Science Session - Room N109/110

NOD-ing off in immunity

Chair Sherlock Jonathan (United Kingdom)
Chair Ospef Caroline (Switzerland)
Speaker McDermott Michael F. (United Kingdom) SP0050 The spectrum of NLR and related molecules in human disease
Speaker Bowcock Anne M. (United Kingdom) CARD14 in psoriasis and psoriatic arthritis
Speaker Lachmann Helen (United Kingdom) Treatment of NLRP3 related disease – a success story with wider implications?
Abstract Fassl Selina (Germany) OP0024 THE FUNCTION OF PSTPIP1 AND S100A8/S100A9 IN HYPERZINCAEMIA & HYPERCALPROTECTINAEMIA AND THE PAPA-SYNDROM

Basic and Translational Science Session - Room N113/114

Teaching lessons on inflammation from cancer therapy

Chair Mariette Xavier (France)
Chair Zitvogel Laurence (France)
Speaker Callhan Maggie (United States) Cancer therapy with Anti-CTLA4 and inflammation
Speaker Robert Caroline (France) Cancer therapy with Anti-PD1 and PD1 ligand and inflammation
Speaker Zitvogel Laurence (France) Anti-tumoral vaccination, new targeted therapy in cancer and inflammation
Abstract Nocturne Gaetane (France) OP0023 GERMINAL AND SOMATIC GENETIC VARIANTS OF TNFAIP3 PROMOTE LYMPHOMAGENESIS PROCESS COMPLICATING PRIMARY SJÖGREN’S SYNDROME

Practical Skills Session - Room N117

Laboratory Course 2

Chair Burmester Gerd Rüdiger (Germany)
Chair Dörner Thomas (Germany)
Speaker Wiik Allan (Denmark) Anti-citrullinated peptide antibodies and neutrophil-specific antibodies
Speaker Dörner Thomas (Germany) Current aspects of ANA and antiphospholipid antibody detection
Speaker Miossec Pierre (France) Cytokine detection: methods & interpretation
Speaker Dörner Thomas (Germany) Discussion and Q&A

Thursday 13.06.2013 10:15 - 11:45

What is New (WIN) - Hall 6
WIN Session 2

Speaker McBeth John (United Kingdom)  Pain and Fibromyalgia
Speaker Manger Bernhard (Germany)  SP0051 Metabolic arthropaties and other rheumatic diseases

Abstract Session - Hall 8

Abstract Session: Osteoarthritis
Chair Mastbergen Simon (Netherlands)
Chair Bevers Karen (Netherlands)
Abstract De Lange-Broekaar B (Netherlands)  OP0025 DIFFERENT PATTERNS OF SYNOVITIS PRESENT IN OA PATIENTS ASSOCIATE DIFFERENTIALLY WITH PAIN.
Abstract Shirinsky Ivan (Russian Federation)  OP0026 DIABETES EFFECTS ON PAIN AND PHYSICAL FUNCTION IN INCIDENCE AND PROGRESSION SUBCOHORTS OF THE OSTEOARTHRITIS INITIATIVE: A 5-YEAR LONGITUDINAL DATA ANALYSIS.
Abstract Haugen Ida Kristin (Norway)  OP0027 HAND OSTEOARTHRITIS (OA) AND THE ASSOCIATIONS TO MORTALITY AND CARDIOVASCULAR EVENTS - DATA FROM THE FRAMINGHAM STUDY
Abstract Martel-Pelletier Johanne (Canada)  OP0028 THE DISEASE MODIFYING EFFECT OF STRONTIUM RANELATE IN A PHASE III KNEE OSTEOARTHRITIS STUDY (SEKOIA).
Abstract Shirinsky Ivan (Russian Federation)  OP0029 USING QUANTITATIVE MAGNETIC RESONANCE IMAGING: REDUCTION IN BONE MARROW LESION SIZE ASSOCIATED WITH CARTILAGE PROTECTIVE EFFECT
Abstract Ramonda Roberta (Italy)  OP0030 OSTEOARTHRITIS AND BONE MINERAL DENSITY OF THE HAND
Abstract Henrotin Yves (Belgium)  OP0031 BASELINE MEASUREMENTS OF COLL2-1 AND COLL2-1NQ2 IN URINE ARE HIGHLY PREDICTIVE OF JOINT SPACE NARROWING IN KNEE OSTEOARTHRITIS
Abstract Roddy Edward (United Kingdom)  OP0032 POPULATION PREVALENCE OF SYMPTOMATIC RADIOGRAPHIC FOOT OSTEOARTHRITIS IN COMMUNITY-DWELLING OLDER ADULTS: THE CLINICAL ASSESSMENT STUDY OF THE FOOT (CASF)

How to Treat / Manage (HOT) - Hall 7

HOT Session 3

Speaker Bardin Thomas (France)  Gout and other crystal diseases
Speaker Conaghan Philip (United Kingdom)  Imaging in Diagnosis and Management

Abstract Session - Room N103/104

Abstract session: Clinical scleroderma and myositis
Chair Valenti Gabriele (Italy)
Chair Dani Lara (Sweden)
Abstract Van Den Hoogen Frank (Netherlands)  OP0033 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS: PRELIMINARY RESULTS
Abstract Jordan Suzana (Switzerland)  OP0034 PERFORMANCE OF THE NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE
Abstract Tjärnlund Anna (Sweden)  OP0035 PROGRESS REPORT ON THE DEVELOPMENT OF NEW CLASSIFICATION CRITERIA FOR ADULT AND JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES
Abstract Denton Christopher (United Kingdom)  OP0036 AN EVIDENCE-BASED TOOL FOR DETECTION OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: THE DETECT STUDY
Abstract Yamasaki Yoshioki (Japan)  OP0037 DERIVATION AND VALIDATION OF A FORMULA FOR SCREENING AND IDENTIFICATION OF EARLY PULMONARY HYPERTENSION USING EXERCISE DOPPLER ECHOCARDIOGRAPHY IN PATIENTS WITH CONNECTIVE TISSUE DISEASES
Abstract Abou-Raya Anna (Egypt)  OP0038 EFFECTS OF ANGIOTENSIN II RECEPTOR BLOCKADE IN SYSTEMIC SCLEROSIS: RANDOMIZED CONTROLLED TRIAL
Abstract  Park Jin Kyun (Korea, Republic Of)  OP0039  HEAD TO HEAD COMPARISON OF UDENAFIL VERSUS AMLODIPINE IN THE TREATMENT OF SECONDARY RAYNAUD’S PHENOMENON: A DOUBLE-BLIND, RANDOMIZED CROSS-OVER STUDY

Abstract  Machado Pedro (United Kingdom)  LB0002  SAFETY AND TOLERABILITY OF ARIMOCLOMOL IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIA PROOF-OF-CONCEPT TRIAL

Abstract Session - Hall 4

Abstract session: RA therapy beyond TNF Inhibition

Chair  Gottenberg Jacques-Eric (France)

Chair  van der Woude Diane (Netherlands)

Abstract  Takeuchi Tsutomu (Japan)  OP0040  ADDING TOCILIZUMAB OR SWITCHING TO TOCILIZUMAB MONOTHERAPY IN RA PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE: 24-WEEK RESULTS FROM A RANDOMIZED CONTROLLED STUDY (SURPRISE STUDY)

Abstract  Burmester G (Germany)  OP0041  TOCILIZUMAB (TCZ) IN COMBINATION AND MONOTHERAPY VERSUS METHOTREXATE (MTX) IN MTX-NAIVE PATIENTS (PTS) WITH EARLY RHEUMATOID ARTHRITIS (RA): CLINICAL AND RADIOGRAPHIC OUTCOMES FROM A RANDOMISED, PLACEBO-CONTROLLED TRIAL

Abstract  Huizinga Tom J. (Netherlands)  OP0042  CLINICAL AND RADIOGRAPHIC OUTCOMES AT TWO YEARS AND THE EFFECT OF TOCILIZUMAB (TCZ) DISCONTINUATION FOLLOWING SUSTAINED REMISSION IN THE SECOND YEAR OF THE ACT-RAY STUDY

Abstract  Holz Josefin-Beate (Belgium)  OP0043  TWENTY-FOUR WEEKS OF TREATMENT WITH A NOVEL ANTI-IL-6 RECEPTOR NANOBODY® (ALX-0061) RESULTED IN 84% ACR20 IMPROVEMENT AND 58% DAS28 REMISSION IN A PHASE II STUDY IN RA

Abstract  Schiff Michael (United States)  OP0044  HEAD-TO-HEAD COMPARISON OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB ON BACKGROUND METHOTREXATE IN RA: TWO YEAR RESULTS FROM THE AMPLE STUDY

Abstract  Vital Edward (United Kingdom)  OP0045  SYNOVIAL B CELL STATUS DETERMINES INTENSITY OF RITUXIMAB THERAPY REQUIRED IN RHEUMATOID ARTHRITIS

Abstract  Genovese Mark (United States)  OP0046  TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN A RHEUMATOID ARTHRITIS OPEN-LABEL EXTENSION STUDY FOLLOWING ADALIMUMAB THERAPY IN A PHASE 3 RANDOMISED CLINICAL TRIAL

Abstract  Taylor Peter (United Kingdom)  OP0047  BARICTINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Abstract  Taylor Peter (United Kingdom)  OP0048  OSKIRA-4: A PHASE IIB RANDOMISED, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF FOSTAMATINIB MONOTHERAPY

Abstract Session - Room N101/102

Abstract session: Genetics, genomics and more

Chair  Kurreeman Fina (Netherlands)

Chair  Carmona F. David (Spain)

Abstract  De Rooy Diederik (Netherlands)  OP0049  A GENETIC VARIANT IN THE REGION OF MMP-9 IS ASSOCIATED WITH SERUM LEVELS AND PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS

Abstract  Steel Kathryn (United Kingdom)  OP0050  FINE MAPPING AND EXPRESSION OF A LOCUS OVERLAPPING 3 TYPES OF INFLAMMATORY ARTHRITIS

Abstract  Webster Amy (United Kingdom)  OP0051  DIFFERENTIAL METHYLATION RELATED TO RESPONSE TO ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS

Abstract  Jiang Xia (Sweden)  OP0052  A DENSE MAPPING OF HLA REGION FOR STUDY OF INTERACTION WITH SMOKING IN THE DEVELOPMENT OF RHEUMATOID ARTHRITIS

Abstract  Govind Nimnisha (South Africa)  OP0053  HLA DRB1 AMINO ACID POSITION 11 IS STRONGLY ASSOCIATED WITH SEROPOSITIVE RHEUMATOID ARTHRITIS IN BLACK SOUTH AFRICANS

Abstract  Tost Jorg (France)  OP0054  HIGH-THROUGHPUT DNA METHYLATION ANALYSIS OF CELL SORTED BLOOD CELL POPULATIONS REVEALS WIDESPREAD EPIGENETIC Deregulation IN SJOGREN’S SYNDROME

Abstract  McAllister Kate (United Kingdom)  OP0055  IMMUNOCHIP VALIDATION STUDY CONFIRMS TWO NOVEL RA SUSCEPTIBILITY LOCI, BACH2 AND RAD51L1


31.05.2013
Abstract Session - Room N105/106

Abstract Session PReS: Clinical and basic developments in paediatric rheumatology

Chair
Prakken Berent J. (Netherlands)
Ozen Seza (Turkey)
Vastert Sebastiaan (Netherlands)
Costa-Reis Patricia (United States)
Ruperto Nicolino (Italy)
De Benedetti F (Italy)
Olivecrona Hans (Sweden)
Windschall Daniel (Germany)
Schmeling Heinrike (Canada)

Abstract Session - Room Retiro

Abstract session: RA: anti-TNF therapy

Chair
St. Clair E. William (United States)
Schulze-Koops Hendrik (Germany)

Abstract
Hassan C (Italy)
Strand Vibeke (United States)
Heather Eleanor (United Kingdom)
Fautrel Bruno (France)
Burmester Gerd (Germany)
Yoo Dae Hyun (Korea, Republic Of)
Manders Sofie (Netherlands)
Singh Jasvinder (United States)

Abstract: THE PTPN22/CSK SIGNALLING PATHWAY IS INVOLVED IN SUSCEPTIBILITY TO DEVELOP GIANT CELL ARTERITIS.

Abstract: ANTI-TNF THERAPY TARGETS PKB/C-AKT INDUCED RESISTANCE OF EFFECTOR CELLS TO SUPPRESSION IN JUVENILE IDIOPATHIC ARTHRITIS

Abstract: MIR-26A AND MIR-30B DYSREGULATION IN PEDIATRIC LUPUS NEPHRITIS

Abstract: A RANDOMIZED TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS: PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE VERSUS PREDNISONE PLUS METHOTREXATE

Abstract: EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM A PHASE 3 TRIAL

Abstract: KINERET® (ANAKINRA) CONTROLS DISEASE SYMPTOMS IN PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): UP TO 5-YEAR FOLLOW-UP DATA

Abstract: SAFETY AND EFFICACY OF ETANERCEPT IN CHILDREN WITH THE JIA CATEGORIES EXTENDED OLIGOARTHRITIS, ENTHESITIS RELATED ARTHRITIS AND PSORIASIS ARTHRITIS

Abstract: EFFICACY AND SAFETY OF ADALIMUMAB IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

Abstract Session - Room N107/108

Abstract session: Other orphan diseases

Abstract: ANTI-TNF THERAPY AND TUBERCULOSIS RISK IN RHEUMATIC DISEASES, PSORIASIS, AND IBD: A POOLED-DATA ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.

Abstract: DISCONTINUATION OF BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS (RA): ANALYSIS FROM THE CONSORTIUM OF RHEUMATOLOGY RESEARCHERS OF NORTH AMERICA (CORRONA) DATABASE

Abstract: QUANTIFYING THE ECONOMIC IMPACT OF SERIOUS INFECTIONS FROM ANTI-TNFs FOR RHEUMATOID ARTHRITIS: RESULTS FROM THE BSRBR-RA

Abstract: TARGETING THE LOWEST EFFICACIOUS DOSE FOR RHEUMATOID ARTHRITIS PATIENTS IN REMISSION: CLINICAL AND STRUCTURAL IMPACT OF A STEP-DOWN STRATEGY TRIAL BASED ON PROGRESSIVE SPACING OF TNF-BLOCKER INJECTIONS (STRASS TRIAL)

Abstract: EFFICACY, PHARMACOKINETICS, AND SAFETY OF DIFFERENT DOSES OF METHOTREXATE IN COMBINATION WITH ADALIMUMAB: RESULTS FROM THE CONCERTO TRIAL

Abstract: A PHASE 3 RANDOMISED CONTROLLED TRIAL TO COMPARE CT-P13 WITH INFliximab IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: 54 WEEK RESULTS FROM THE PLANETA STUDY

Abstract: SIGNIFICANTLY BETTER RESULTS FOR TNFi COMBINATION THERAPY WITH MTX THAN TNFI MONO- AND COMBINATION WITHOUT MTX THERAPY IN PATIENTS WITH RA: RESULTS FROM THE DREAM REGISTRY

Abstract: RISK OF CANCER, SERIOUS LUNG INFECTIONS AND DEATH WITH BIOLOGICS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS)
INCOME AND PATIENT-REPORTED OUTCOMES (PROS) AFTER PRIMARY TOTAL KNEE ARTHROPLASTY

Use of moist snuff and the risk of developing rheumatoid arthritis; results from the Swedish

OP0093

OP0087

Uhlig Till (Norway)

Ramiro Sofia (Portugal)

Singh Jasvinder (United States)

Alfredsson Lars (Sweden)

Income and patient-reported outcomes (PROs) after primary total knee arthroplasty

Use of moist snuff and the risk of developing rheumatoid arthritis; results from the Swedish
Abstract Session - Room N113/114

Abstract Session HPR: Building Blocks for better care

Chair: Niedermann Karin (Switzerland)
Chair: Ferreira Ricardo (Portugal)

Abstract Christie Anne (Norway) OP0095-HPR WHY USE PEN AND PAPER IN DATA COLLECTION WHEN YOU CAN USE A MOBILE PHONE? - COMPARISON OF THE TWO METHODS

Abstract Jennings Fabio (Brazil) OP0096-HPR BENEFITS OF PROGRESSIVE MUSCLE STRENGTHENING USING A SWISS BALL IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A RANDOMIZED CONTROLLED TRIAL.

Abstract Nikolaus Stephanie (Netherlands) OP0097-HPR THE CHALLENGE TO DEVELOP A MULTIDIMENSIONAL COMPUTERIZED ADAPTIVE TEST FOR FATIGUE IN RHEUMATOID ARTHRITIS

Abstract Heine Peter (United Kingdom) OP0098-HPR SARAH: STRENGTHENING AND STRETCHING FOR PEOPLE WITH RHEUMATOID ARTHRITIS OF THE HANDS: A RANDOMISED CONTROLLED TRIAL

Abstract Crins Martine (Netherlands) OP0099 SOMATIC COMORBIDITY IN PATIENTS WITH CHRONIC WIDESPREAD PAIN IN AN OUTPATIENT SECONDARY CARE CENTER FOR RHEUMATOLOGY AND REHABILITATION IN THE NETHERLANDS

Abstract Willems L. (Netherlands) OP0100-HPR EDUCATIONAL NEEDS AMONG HEALTH PROFESSIONALS WORKING WITH SYSTEMIC SCLEROSIS: AN INTERNATIONAL SURVEY CONDUCTED ON BEHALF OF THE EULAR SCLERODERMA HEALTH PROFESSIONALS NETWORK (EUSHNET)

Abstract Van Den Ende Cornelia (Netherlands) OP0101-HPR IN PATIENTS WITH HAND OA THERE IS NO EVIDENCE THAT A BOOSTER SESSION AFTER MULTIDISCIPLINARY TREATMENT IS EFFECTIVE: RESULTS OF A RANDOMISED CONTROLLED TRIAL

Abstract Loeppenthin Katrine (Denmark) OP0102-HPR SEDENTARY BEHAVIOUR IN DANISH PATIENTS WITH RHEUMATOID ARTHRITIS - WHAT IS THE ASSOCIATION TO PAIN, FATIGUE, SLEEP AND PHYSICAL FUNCTION? A CROSS-SECTIONAL STUDY

Abstract Session - Room N117

Abstract Session: Management of spondylarthropathy and psoriatic arthritis

Chair: Braun Jürgen (Germany)
Chair: van Gaalen Floris A. (Netherlands)

Abstract Mease Philip (United States) OP0103 EFFICACY OF BRODALUMAB, AN ANTI-IL-17R ANTIBODY, IN SUBJECTS WITH PSORIATIC ARTHRITIS

Abstract Edwards Chris (United States) OP0104 APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS INCLUDING CURRENT SKIN INVOLVEMENT: RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL

Abstract Mease Philip (United States) OP0105 EFFECT OF ADAILUMAB ON PHYSICAL FUNCTION, HEALTH-RELATED QUALITY OF LIFE, AND WORK PRODUCTIVITY IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS: RESULTS FROM THE ABILITY-2 CLINICAL TRIAL

Abstract Landewé Robert (Netherlands) OP0106 EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Abstract Van Nies Jessica (Netherlands) OP0091 WHAT IS THE EVIDENCE FOR THE PRESENCE OF A THERAPEUTIC WINDOW OF OPPORTUNITY IN RHEUMATOID ARTHRITIS? A SYSTEMATIC LITERATURE REVIEW

Abstract Westhoff Gisela (Germany) OP0092 INDICATORS OF DEPRESSION ARE STRONGER PREDICTORS OF WORK DISABILITY IN EARLY ARTHRITIS THAN DISEASE ACTIVITY OR RESPONSE TO THERAPY

Abstract Karlsson Johan (Sweden) OP0094 COST-EFFECTIVENESS OF BIOLOGIC VERSUS CONVENTIONAL COMBINATION TREATMENT IN EARLY RHEUMATOID ARTHRITIS: 2-YEAR RESULTS OF THE RANDOMISED CONTROLLED SWEFOT TRIAL

Abstract Verstappen Suzanne (United Kingdom) OP0088 CHANGES IN BASELINE SEVERITY OF INFLAMMATORY POLYARTHITIS OVER TIME

Abstract Verstappen Suzanne (United Kingdom) OP0089 DISEASE SEVERITY IN PATIENTS WITH INFLAMMATORY ARTHRITIS WHO PERSISTENTLY, INTERMITTENTLY, OR NEVER ACHIEVE REMISSION

Abstract Hetland Merete Lund (Denmark) OP0090 DURATION OF SYMPTOMS BEFORE DIAGNOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
Abstract

van der Heijde Desiree (Netherlands)  
OP0107  
SPECIFIC IDENTIFICATION OF ANTI-CITRULLINATED GLUCOSE-6-PHOSPHATE ISOMERASE PEPTIDE (CCG) ANTIBODIES: IMPROVEMENTS IN WORK AND HOUSEHOLD PRODUCTIVITY AFTER 24 WEEKS OF CERTOLIZUMAB PEGOL IN TREATMENT OF AXIAL SPONDYLOARTHRITIS PATIENTS, INCLUDING PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF RAPID-AXSFA STUDY

Abstract

Dougados Maxime (France)  
OP0108  
CLINICAL AND IMAGING EFFICACY OF ETANERCEPT IN EARLY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Abstract

Sieper Joachim (Germany)  
OP0109  
SUSTAINED CLINICAL REMISSION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AFTER TWO YEARS OF ADALIMUMAB TREATMENT

Abstract

Smolen Josef (Austria)  
OP0110  
TREAT-TO-TARGET RECOMMENDATIONS FOR SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A CONSENSUS OF AN INTERNATIONAL TASK FORCE

Abstract

Gossec Laure (Switzerland)  
OP0111  
ELABORATION AND PRELIMINARY VALIDATION OF THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAIQ) QUESTIONNAIRE. A 13-COUNTRY EULAR INITIATIVE WITH INVOLVEMENT OF PATIENT RESEARCH PARTNERS FROM EACH COUNTRY.

Abstract Session - Room N118

Chair  
Theander Elke (Sweden)
Laskari Katerina (Germany)

Abstract

Meiners Petra (Netherlands)  
OP0112  
ABATACEPT TREATMENT REDUCES DISEASE ACTIVITY IN EARLY PRIMARY SJÖGREN'S SYNDROME (PHASE II OPEN LABEL ASAP STUDY)

Abstract

Seror Raphaële (France)  
OP0113  
MODIFICATION OF SALIVARY GLAND LYMPHOCYTE PATTERN AFTER BELIMUMAB IN PRIMARY SJÖGREN'S SYNDROME: RESULTS OF THE BELISS STUDY

Abstract

Gottenberg Jacques Eric (France)  
OP0114  
INEFFICACY OF HYDROXYCHLOROQUINE IN PRIMARY SJÖGREN'S SYNDROME: RESULTS AT 12 MONTHS OF THE RANDOMIZED PLACEBO-CONTROLLED TRIAL OF PLAQUELIN IN PRIMARY SJÖGREN'S SYNDROME

Abstract

De Vries Jane (United Kingdom)  
OP0115  
EFFICACY OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH HIGH DISEASE ACTIVITY IN KEY ORGAN SYSTEMS: BLISS SUB-POPULATIONS

Abstract

Furie Richard (United States)  
OP0116  
EFFECTS OF BLISIBIMOD, A SUBCUTANEOUS INHIBITOR OF B CELL ACTIVATING FACTOR, IN PATIENTS WITH SLE

Abstract

Tselios Konstantinos (Greece)  
OP0117  
CYCLOPHOSPHAMIDE PULSE THERAPY LEADS TO T REGULATORY CELLS ALTERATIONS IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract

Goldenberg David (United States)  
OP0118  
EPRATUZUMAB MEDIATES BCR-ANTIGEN TROGOCYTOSIS AS POTENTIAL MECHANISM OF ACTION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Abstract

Wofsy D (United States)  
OP0119  
PHARMACODYNAMIC EFFECTS OF ATACICEPT IN SLE PATIENTS: 52-WEEK DATA FROM THE APRIL-SLE TRIAL

Abstract

Jayne David (United Kingdom)  
LB0003  
A RANDOMIZED CONTROLLED STUDY OF LAQUINIMOD IN ACTIVE LUPUS NEPHRITIS PATIENTS IN COMBINATION WITH STANDARD OF CARE

Abstract Session - Room N115

Chair  
Humby Frances (United Kingdom)
Filer Andrew (United Kingdom)

Abstract

Umeda Naoto (Japan)  
OP0120  
SPECIFIC IDENTIFICATION OF ANTI-CITRULLINATED GLUCOSE-6-PHOSPHATE ISOMERASE PEPTIDE (CCG) ANTIBODIES ASSOCIATED WITH HLA-DRB1 SE AND DISEASE ACTIVITY IN PATIENTS WITH RA

Abstract

Binks Daniel (United Kingdom)  
OP0121  
THE FREQUENCY OF BONE EROSION AND OEDEMA IN INFLAMMATORY AND DEGENERATIVE ARTHROPATHIES PROXIMAL TO THE PERI-ENTHESEAL CRUCIATE LIGAMENT VASCULAR CHANNELS.
Rebranding rheumatic and musculoskeletal diseases - what is so special about RMDs?

Chair: Olsson Magdalena (Sweden)
Speaker: Mateus Elsa (Portugal)
Speaker: Brezniceanu Ana Maria (Romania)
Speaker: Raza Karim (United Kingdom)
Speaker: Machold Klaus (Austria)
Speaker: Kosanovic Marija (Serbia)

Tackling the image issue of RMDs through marketing
“RMDs – articulated emotions” – a joint project between the Romanian League against Rheumatism and Romanian artists to improve the image of RMDs in the general population
Delays in help seeking and referral: problems and potential solutions in the context of inflammatory arthritis
Immediate access to rheumatology - are quicker answers better answers?

MOVE TO IMPROVE? FASHION SHOW ? CELEBRATING 2012 WORLD ARTHRITIS DAY IN SERBIA

Thursday 13.06.2013 12:00 - 13:15

Poster Tour - Poster Area

Abstract: van den Bosch Marlijn (Netherlands) OP0122 SYNVOIAL WNT AND WISP1 EXPRESSION INDUCES EXPRESSION OF CARTILAGE-DEGRADING METALLOPROTEINASES IN THE SYNOVIAL
Abstract: Haqqi Tariq (United States) OP0123 IN HUMAN CHONDROCYTES DNMT-1 PLAYS A KEY ROLE IN THE EXPRESSION OF SEVERAL GENES ASSOCIATED WITH THE PATHOGENESIS OF OSTEOARTHRITIS
Abstract: Lin Neng Yu (Germany) OP0124 INHIBITION OF AUTOPHAGY RESCUE THE BONE LOSS OF EXPERIMENTAL OSTEOPOROSIS
Abstract: Laigüillon M-C. (France) OP0125 VISFATIN/NAMPT IN OSTEOARTHRITIS: A PRO-INFLAMMATORY ADIPOKINE INVOLVED IN SYNOVIAL-CARTILAGE AND SYNOVIAL-BONE COMMUNICATIONS
Abstract: Berenbaum Francis (France) OP0126 SECRETED 14-3-3? : DISCOVERY BY PROTEOMICS OF A NEW SUBCHONDRAL BONE MEDIATOR INVOLVED IN CARTILAGE DEGRADATION DURING OSTEOARTHRITIS
Abstract: Im Gun-II (Korea, Republic Of) OP0127 IN VITRO CHONDROGENESIS AND IN VIVO REPAIR OF OSTEOCHONDRAL DEFECT WITH HUMAN INDUCED PLURIPOTENT STEM CELLS

THU0599-HPR
THU0597-HPR
THU0596-HPR
THU0593-HPR
THU0594-HPR
THU0595-HPR
THU0596-HPR
THU0597-HPR
THU0598-HPR
THU0599-HPR

FREQUENCY AND IMPACT OF DISEASE SYMPTOMS EXPERIENCED BY PATIENTS WITH SYSTEMIC SCLEROSIS: A COMPARISON AMONG FIVE EUROPEAN COUNTRIES
IMPROVED PSYCHOLOGICAL WELL-BEING AND PHYSICAL FUNCTIONING IN RHEUMATOID ARTHRITIS: A COHORT STUDY COVERING TWO DECADES
ADAPTATION AND VALIDATION OF THE EDUCATION NEEDS ASSESSMENT TOOL INTO POLISH: A CROSS SECTIONAL, TOOL VALIDATION STUDY
TIGHT CONTROL WITH REGULAR REVIEW FOR RHEUMATOID ARTHRITIS IN A DGH - REDUCES THE USE OF BIOLOGIC THERAPY ACCORDING TO NICE GUIDELINES EVEN IF MODERATE DISEASE ACTIVITY WAS TREATED
EFFECTIVENESS OF A GROUP-BASED INTERVENTION TO IMPROVE MEDICATION BELIEFS AND ADHERENCE IN NON-ADHERENT PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED CONTROLLED TRIAL
DISSEMINATION AND EVALUATION OF THE EULAR RECOMMENDATIONS FOR THE ROLE OF THE NURSE IN THE MANAGEMENT OF CHRONIC INFLAMMATORY ARTHRITIS
FROM BAD TO WORSE? THE IMPACT OF SWITCHING BIOLOGIC AGENTS MULTIPLE TIMES ON WORK PRODUCTIVITY AND HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH RA.
Abstract
Kool Marianne (Netherlands)

THU0600-HPR
RHEUMATOLOGISTS? LACK OF UNDERSTANDING AND DISCOUNTING FOR PATIENTS WITH FIBROMYALGIA AND RHEUMATOID ARTHRITIS

**Poster Tour: Finding new targets in RA**

Chair
Bijlma Johannes W.J. (Netherlands)

Chair
Michels-van Amsfort J.M.R (Netherlands)

Abstract
Ramwadthdeebe Tamara (Netherlands)

THU0111
T-CELL SUBSETS IN LYMPH NODE BIOPSIES OF AUTOANTIBODY POSITIVE SUBJECTS AT RISK OF RHEUMATOID ARTHRITIS (RA) AND EARLY RA PATIENTS.

Abstract
Fujii Wataru (Japan)

THU0112
MYELOID-DERIVED SUPPRESSOR CELLS HAVE REGULATORY ROLES IN MOUSE COLLAGEN-INDUCED ARTHRITIS

Abstract
Barbarroja Nuria (Spain)

THU0113
ANTI-CYCLIC CITRULLINATED PROTEIN ANTIBODIES ACT AS DIRECT INDUCERS OF THE INFLAMMATION AND THE OXIDATIVE STRESS OBSERVED IN RHEUMATOID ARTHRITIS, WITH DIFFERENTIAL EFFECTS IN EACH WHITE BLOOD CELL TYPE

Abstract
Tomcik Michal (Czech Republic)

THU0114
THE LOSS OF S100A4 PREVENTS JOINT DESTRUCTION AND SYSTEMIC BONE LOSS IN HTNFTG MOUSE MODEL

Abstract
Trenkmann Michelle (Switzerland)

THU0115
EPIGENETIC REPRESSION OF THE LONG NONCODING RNA HOTAIR REGULATES NF-KB SIGNALLING AND THE EXPRESSION OF MATRIX METALLOPROTEASES IN SYNOVIAL FIBROBLASTS

Abstract
Galien Rene (France)

THU0116
BIOLOGICAL EFFECTS OF THE JAK1 SELECTIVE INHIBITOR GLPG0634 ON INFLAMMATION MARKERS IN ARTHRITIC MICE

Abstract
Blöni Stephan (Austria)

THU0117
LOSS OF PTEN IN MYELOID CELLS CONTROLS INFLAMMATORY BONE DESTRUCTION BY REGULATING THE OSTEOCLASTOGENIC POTENTIAL OF MYELOID CELLS

Abstract
Skriner Karl (Germany)

THU0118
TOLL-LIKE RECEPTOR DEPENDENT AUTOANTIGENS IN ANIMAL MODELS AND HUMANS IN USE TO IMPROVE COLLAGEN INDUCED ARTHRITIS.

Abstract
Suzuki Miho (Japan)

THU0119
ANTI-IL-6 RECEPTOR ANTIBODY IS EFFECTIVE IN TREATING ARTHRITIS IN OBESE MICE

**Poster Tour: Genetics and beyond**

Chair
Toes Rene (Netherlands)

Chair
Carmona F. David (Spain)

Abstract
Ferreiro-Iglesias Aida (Spain)

THU0001
REPLICATION OF INTERACTIONS BETWEEN POLYMORPHISMS IN RHEUMATOID ARTHRITIS SUSCEPTIBILITY

Abstract
Martin Paul (United Kingdom)

THU0002
COMPARISON OF PATHWAYS IMPLICATED IN ANTI-CITRULLINATED PEPTIDE ANTIBODY POSITIVE AND NEGATIVE RHEUMATOID ARTHRITIS PATIENTS

Abstract
Pavek Nikolas (Czech Republic)

THU0003
CORRELATION OF MIR-124 TO EXTRACELLULAR MATRIX PROTEIN MMP-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Abstract
Hawtree Sarah (United Kingdom)

THU0004
THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS FIBROBLASTS-LIKE SYNOVIOCYTES

Abstract
Streicher Katie (United States)

THU0005
INVESTIGATING THE PLASMA CELL SIGNATURE IN AUTOIMMUNE DISEASE

Abstract
Marsal Sara (Spain)

THU0006
PDE3A-SLC01C1 LOCUS IS ASSOCIATED WITH THE RESPONSE TO ANTI-TUMOR NECROSIS FACTOR THERAPY IN RHEUMATOID ARTHRITIS

Abstract
Ibrahim Ibrahim (United Kingdom)

THU0007
INVESTIGATION OF CRP GENE POLYMORPHISMS AS PREDICTORS OF CARDIOVASCULAR MORTALITY IN INFLAMMATORY POLYARHTHRITIS ? RESULTS FROM THE NORFOLK ARTHRITIS REGISTER.

Abstract
Juarez Maria (United Kingdom)

THU0008
SERIAL ANALYSIS OF GENE EXPRESSION OF SYNOVIAL FIBROBLASTS DISCRIMINATES BETWEEN RESOLVING AND PERSISTENT INFLAMMATORY ARTHRITIS

Abstract
Montes Ariana (Spain)

THU0009
REDUCED CLINICAL IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS SHOWING IGG1 ALLOTYPE -INFliximab INCOMPATIBILITY

Abstract
Yarwood Annie (United Kingdom)

THU0010
A WEIGHTED GENETIC RISK SCORE USING 46 LOCI TO PREDICT RHEUMATOID ARTHRITIS RISK

**Poster Tour: Innate and adaptive immunity**

Chair
Pitzalis Costantino (United Kingdom)

Chair
Scherer Hans-Ulrich (Netherlands)

Abstract
Mcgarry Trudy (Ireland)

THU0009
7-INTTEGRIN IS A CRITICAL MEDIATOR OF TLR2-INDUCED MIGRATIONAL AND INVASIVE MECHANISMS IN RA SYNOVIAL
FIBROBLAST CELLS

Abstract Byrne Ruth (Austria) THU0040
REALTIME ANALYSIS OF MONOCYTE MIGRATION IN 3D SYNOVIAL MICROMASS TISSUE CULTURES

Abstract Frank Bertoneč Moja (Switzerland) THU0041
MICROPARTICLE-ASSOCIATED POLY(I:C) IS RESISTANT TO RNASE III DEGRADATION AND PROTECTS RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS FROM TRAIL-INDUCED APOPTOSIS

Abstract Garcia Samuel (Netherlands) THU0042
COLONY-STIMULATING FACTOR (CSF) RECEPTOR 1 BLOCKADE OVERCOMES OVERLAPPING EFFECTS OF M-CSF AND INTERLEUKIN-34 ON MYELOID DIFFERENTIATION AND GENE EXPRESSION TO REDUCE INFLAMMATION IN HUMAN AND MURINE MODELS OF RHEUMATOID ARTHRITIS

Abstract Toussirot Eric (France) THU0043
THE ALTERNATIVE CD20 TRANSCRIPT VARIANT IS NOT EXPRESSED IN B CELLS AND SYNOVIAL TISSUE FROM PATIENTS WITH RHEUMATOID ARTHRITIS

Abstract Bugatti Serena (Italy) THU0044
SYNOVIAL AND SERUM LEVELS OF THE B-CELL ATTRACTING CHEMOKINE CXCL13 IN RHEUMATOID ARTHRITIS ARE RELATED TO EACH OTHER AND ASSOCIATE WITH MARKERS OF LYMPHOCYTE ACTIVATION AND DISEASE SEVERITY

Abstract Lumb Simon (United Kingdom) THU0045
1,25(OH)2D3 INHIBITS TH17 POLARIZATION AND RORC EXPRESSION THROUGH GATA3-DEPENDENT AND -INDEPENDENT MECHANISMS

Poster Tour: Management of SpA 1

Chair van der Heijde Désirée (Netherlands)
Chair Navarro-Compán Victoria (Spain)

Abstract van der Heijde Désirée (Netherlands) THU0361
RELATIONSHIP BETWEEN MRI AND CLINICAL REMISSION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHITIS AFTER TWO YEARS OF ADALIMUMAB THERAPY

Abstract Nystad Tone (Norway) THU0362
HIP REPLACEMENT SURGERY IN PATIENTS WITH ANKYLOSING SPONDYLITIS

Abstract Kristensen Lars (Sweden) THU0363
EFFICACY AND TOLERABILITY OF ANTI-TNF THERAPIES IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHITIS: AN OBSERVATIONAL COHORT STUDY FROM SOUTHERN SWEDEN

Abstract Kneepkens E (Netherlands) THU0364
LOWER ETANERCEPT LEVELS ARE ASSOCIATED WITH HIGH DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS PATIENTS AT 24 WEEKS OF FOLLOW-UP

Abstract Boonen Annelies (Netherlands) THU0365
WORK PRODUCTIVITY IN A COHORT OF EMPLOYED ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH ETANERCEPT

Abstract Pedersen Susanne Juhl (Denmark) THU0366
EFFICACY OF ADALIMUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF AN INVESTIGATOR-INITIATED 12-WEEKS RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL WITH A 12 WEEKS OPEN-LABEL EXTENSION PHASE

Abstract Paramarta Jacqueline (Netherlands) THU0367
FAST RELAPSE UPON DISCONTINUATION OF TUMOR NECROSIS FACTOR BLOCKING THERAPY IN PATIENTS WITH PERIPHERAL SPONDYLOARTHITIS

Abstract Almirall Miriam (Spain) THU0368
DOSE REDUCTION OF BIOLOGICAL THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHITIS IN PERSISTENT CLINICAL REMISSION.

Abstract Haugeberg Glenn (Norway) THU0369
THE EFFECT OF ANTI-TNF TREATMENT IN AXIAL SPONDYLOARTHITIS PATIENTS TREATED IN ORDINARY CLINICAL PRACTICE ? RESULTS FROM TWO BIORHEUMA CLINICS IN NORWAY

Poster Tour: Osteoporosis

Chair Buttgereit Frank (Germany)
Chair Spies Cornelia (Germany)

Abstract Adami Silvano (Italy) THU0412
PREVALENCE AND INCIDENCE OF OSTEOPOOROTIC FRACTURES IN PATIENTS ON LONG-TERM GLUCOCORTICOID TREATMENT FOR RHEUMATIC DISEASES: THE GLUCOCORTICOID INDUCED OSTEOPOROSIS TOOL, GIOTTO STUDY.

Abstract Torrent Anna (Spain) THU0413
NEW FORMULATION WITH POTENTIAL FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS AND OSTEOARTHRITIS
Abstract  Briot Karine (France) THU0414 TRABECULAR BONE SCORE: A TOOL FOR IDENTIFICATION OF SEVERE SPINAL OSTEOPOROSIS
Abstract  Kakar Atul (India) THU0415 AN AUDIT OF ACUTE SIDE EFFECT PROFILE OF ZOLEDRONIC ACID, INNOVATOR VERSUS GENERIC PREPARATION
Abstract  Grygiel-Gorniak Bogna (Poland) THU0416 NUTRITIONAL RISK FACTORS OF POSTMENOPAUSAL OSTEOPOROSIS
Abstract  Siluentes Giraldo Walter (Spain) THU0417 UVEITIS ASSOCIATED WITH BISPHOSPHONATE TREATMENT: A CASE SERIES OF 18 PATIENTS.
Abstract  Roux C (France) THU0418 DENOSUMAB VERSUS RISEDRONATE: EFFICACY AND SAFETY IN POSTMENOPAUSAL WOMEN SUBOPTIMALLY ADHERENT TO ALENDRONATE THERAPY IN A RANDOMIZED OPEN-LABEL STUDY
Abstract  Oldroyd Alexander (United Kingdom) THU0419 THE APPROPRIATE AGE OF TESTING FOR LOW BMD IN MEN WITH DXA: AN OBSERVATIONAL STUDY
Abstract  Petrova Elena (Russian Federation) THU0420 THE ASSOCIATION BETWEEN BONE MINERAL DENSITY AND EROSIIVE, DESTRUCTIVE CHANGES IN PATIENTS WITH RHEUMATOID ARTHRITIS.

### Poster Tour: Small Molecules: New and old revisited
Chair  Aletaha Daniel (Austria)
Chair  Myasoedova Elena (United States)
Abstract  Kumagai Shunichi (Japan) THU0220 ESTABLISHMENT OF A PREDICTION MODEL FOR HEPATOXICITY OF METHOTREXATE BY USING OMET MICROARRAY PROFILING IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract  Gaujoux-Viala Cécile (France) THU0221 METHOTREXATE OPTIMIZATION (IE INTRODUCTION DURING THE FIRST 3 MONTHS AND WITH DOSE ESCALATION AT 6 MONTHS AT LEAST AT 20MG/W OR 0.3MG/KG/W) IS ASSOCIATED WITH BETTER CLINICAL OUTCOMES IN DAILY PRACTICE: RESULTS FROM THE ESPOIR COHORT
Abstract  Movahedi Mohammad (United Kingdom) THU0222 ORAL GLUCOCORTICOIDS AND THE RISK OF INCIDENT TYPE II DIABETES MELLITUS IN PATIENTS WITH RHEUMATOID ARTHRITIS, A RETROSPECTIVE COHORT STUDY
Abstract  Yamanishi K. (Japan) THU0223 THE NOVEL CPLA2 INHIBITOR AK106-001616 IS A NEW CATEGORY OF ANTI-INFLAMMATORY/ANALGESIC DRUG DEMONSTRATING EFFICACY AND FAVORABLE TOLERABILITY IN THE TREATMENT OF RHEUMATOID ARTHRITIS.
Abstract  O’Dell James (United States) THU0224 RANDOMIZED DOUBLE-BLIND COMPARATIVE EFFECTIVENESS IN RA PATIENTS WITH ACTIVE DISEASE DESPITE METHOTREXATE (MTX): A COMPARISON OF CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS WITH A BIOLOGICAL.
Abstract  Huizinga Tom J. (Netherlands) THU0225 TOFACITINIB MONOTHERAPY IS EFFECTIVE IN METHOTREXATE-NAIVE PATIENTS WITH DISEASE DURATION LESS THAN 6 MONTHS: A POST-HOC ANALYSIS OF EARLY RHEUMATOID ARTHRITIS SUBJECTS IN A PHASE 3 TRIAL
Abstract  Kremer Joel (United States) THU0226 BARICITINIB EFFECTS ON SERUM CHOLESTEROL AND CIRCULATING LIPID PARTICLES IN A PHASE 2B STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract  Garg Jay (United States) THU0227 POOLED ANALYSIS OF CLINICAL SAFETY DATA FOR ASP015K, A NOVEL JAK INHIBITOR IN DEVELOPMENT FOR TREATMENT OF AUTOIMMUNE DISEASES
Abstract  Keystone E (Canada) THU0228 TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: POST-HOC ANALYSES OF EFFICACY AND SAFETY OF MONOTHERAPY VERSUS COMBINATION THERAPY IN A PHASE 3 RHEUMATOID ARTHRITIS POPULATION
Abstract  Vanhoucke Frédéric (Belgium) THU0229 SAFETY AND EFFICACY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A 4-WEEK PHASE II A DOSE RANGING, MULTI-CENTER TRIAL

### Poster Tour: Spondyloarthritis: basic and translational
Chair  Lories Rik (Belgium)
Chair  Neerinckx Barbara (Belgium)
Abstract  Klavdianou Kalliopi (Greece) THU0342 ANTI-TNF TREATMENT REDUCES SERUM SEROTONIN LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND DOWNREGULATES SEROTONIN SIGNALING IN AN EXPERIMENTAL CELL LINE MODEL
Abstract  Blei Janine (Germany) THU0343 NO UPREGULATION OF IL-6 AT DIFFERENT SITES IN FACET JOINTS OF PATIENTS WITH ANKYLOSING SPONDYLITIS
Abstract

THU0344

Conrad Kristina (Germany)

Reduced LPS-Induced IL-6 Production by Monocytes in Whole Blood Stimulations in Patients with Ankylosing Spondylitis

THU0345

Gu Jieruo (China)

Meloxicam Inhibits the Activation of Serum from Patients with Ankylosing Spondylitis to Wnt/?-Catenin Pathway on MG63

THU0346

Kundzer Alena (Belarus)

DNase Activity of Polyclonal IgGs ? A Putative Serological Marker in Patients with Spondyloarthritides

THU0347

Karoli Nina (Russian Federation)

Central Blood Pressure in Patients with Ankylosing Spondylitis

THU0348

Jackerott Malene (Denmark)

Localisation of IL-20 in Synovium from Patients with Psoriatic Arthritis

THU0349

Akar Servet (Turkey)

Do Major Histocompatibility Complex Tag Single Nucleotide Polymorphisms Accurately Identify HLA-Turkish Ankylosing Spondylitis Patients?

THU0350

ERDEM Hakan (Turkey)

Reduced Thickness and Invasion of the Subchondral Bone Plate by Fibrous Tissue Are Hallmarks of Joint Remodeling in Ankylosing Spondylitis

THU0351

The Role of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) in the Pathogenesis of Ankylosing Spondylitis

Poster Tour: Take care of organs

Chair
Cutolo Maurizio (Italy)

Chair
Sulli Alberto (Italy)

Abstract

Baerlecken Niklas (Germany)

Antibodies Binding to DRP-4 and Macropain Subunit C2 As a Potential Marker of AOSD

Abstract

Anton J (Spain)

Canakinumab Treatment of Patients with Hyper-IgD Syndrome: An Open-Label, Multicenter, Pilot Study

Abstract

Kalyoncu Umut (Turkey)

Delay of Diagnosis in Still's Disease Is Associated With a Chronic/Relapsing Pattern: National, Multicenter Study of 356 Patients

Abstract

Belov Boris (Russian Federation)

Serum ACE for Sarcoidosis Is Not Such an ACE Test

Abstract

Tanaka Shigeru (Japan)

[18F] FDG Uptake in Proximal Muscles Assessed by PET/CT Reflects Both Global and Local Muscular Inflammation and Provides Useful Information in the Management of Patients with Polymyositis/Dermatomyositis

Abstract

Bilik Berivan (Turkey)

Serum Antimicrobial Peptides in Patients with Familial Mediterranean Fever

Poster Tour: Treatment in SLE and Sjögren's syndrome

Chair
Lundberg Ingrid (Sweden)

Chair
Mavragani Clio (Greece)

Abstract

Fischer-Betz Rebecca (Germany)

Low Risk of Renal Flares and of Negative Outcomes in Women with Lupus Nephritis Conceiving After Switching Mycophenolate Mofetil to Azathioprine

Abstract

Molta Charles (United States)

Outcomes in Systemic Lupus Erythematosus (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S)

Abstract

van Vollenhoven Ronald (Sweden)

Off-Label Use of Rituximab for SLE in Europe: A Comparison to Patients Treated with Conventional Immunosuppressive Medications

Abstract

Cobo-Ibáñez Tatiana (Spain)

Rituximab for the Treatment of Non-Renal Systemic Lupus Erythematosus

Abstract

Reggia Rossella (Italy)

Efficacy and Safety of Cyclosporine-A During Pregnancy in Autoimmune Diseases
Clinical aspects of rheumatoid arthritis

Early Arthritis

Gerlag Daniëlle (Netherlands)

Win Session 3

What is New (WIN) - Hall 6

THU0265

A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP

THU0266

EFFECTS OF VARIOUS IMMUNOSUPPRESSANTS IN THE DISEASE DAMAGE AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

THU0267

ULTRASONOGRAPHIC SALIVARY GLANDS RESPONSE TO RITUXIMAB IN PRIMARY SJÖGREN SYNDROME PATIENTS (TEARS SONONOGRAPHIC STUDY)

THU0268

EFFICACY AND SAFETY OF A COMBINED TREATMENT PROTOCOL FOR 2ND DEGREE CONGENITAL HEART BLOCK

THU0269

LIPOSOMAL LOCAL THERAPY AS TREATMENT OF SICCA SYMPTOMS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

THU0270

THE EFFECT OF HYDROXYCHLOROQUINE TO THE LIPID PROFILE OF GREEK PATIENTS WITH SJÖGREN’S SYNDROME

THU0054

ROLE OF FRA-2 IN TLR8-MEDIATED TIMP-1 PRODUCTION IN SYSTEMIC SCLEROSIS

THU0055

THE NUCLEAR RECEPTOR VITAMIN D RECEPTOR REGULATES TGF-ß SIGNALING AND FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS

THU0056

A SMALL CHEMICAL COMPOUND IDENTIFIED AS AN ACE2 ACTIVATOR PREVENTED PULMONARY ARTERIAL HYPERTENSION INDUCED BY MONOCROTALINE

THU0057

INHIBITION OF HEAT SHOCK PROTEIN 90 (HSP90) PREVENTS FIBROSIS BY TARGETING CANONICAL TGF-ß SIGNALING

THU0058

B CELL RECEPTOR EDITING IN SCleroderma PATIENTS GENERATES PATHOGENIC ANTI-PDGFR AUTOANTIBodies

THU0059

DECREASED EXPRESSION OF NEUROPILIN-1 IN SYSTEMIC SCLEROSIS: POTENTIAL CONTRIBUTION TO IMPAIRED ANGIOGENESIS

THU0060

CLINICAL PHENOTYPES OF SYSTEMIC SCLEROSIS IMPACT TELOMERE AND TELOSONE FUNCTION IN DISTINCT PATTERNS

THU0061

CORRELATIONS BETWEEN ANGIoGENIC FACTORS AND CAPILLAROSCOPIC PATTERNS IN SYSTEMIC SCLEROSIS

THU0062

THE POTENTIAL ROLE OF MAST CELLS IN THE C-PROTEIN INDUCED MYOSITIS MODEL

Thursday 13.06.2013 13:30 - 15:00

THU0054

ROLE OF FRA-2 IN TLR8-MEDIATED TIMP-1 PRODUCTION IN SYSTEMIC SCLEROSIS

THU0055

THE NUCLEAR RECEPTOR VITAMIN D RECEPTOR REGULATES TGF-ß SIGNALING AND FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS

THU0056

A SMALL CHEMICAL COMPOUND IDENTIFIED AS AN ACE2 ACTIVATOR PREVENTED PULMONARY ARTERIAL HYPERTENSION INDUCED BY MONOCROTALINE

THU0057

INHIBITION OF HEAT SHOCK PROTEIN 90 (HSP90) PREVENTS FIBROSIS BY TARGETING CANONICAL TGF-ß SIGNALING

THU0058

B CELL RECEPTOR EDITING IN SCleroderma PATIENTS GENERATES PATHOGENIC ANTI-PDGFR AUTOANTIBodies

THU0059

DECREASED EXPRESSION OF NEUROPILIN-1 IN SYSTEMIC SCLEROSIS: POTENTIAL CONTRIBUTION TO IMPAIRED ANGIOGENESIS

THU0060

CLINICAL PHENOTYPES OF SYSTEMIC SCLEROSIS IMPACT TELOMERE AND TELOSONE FUNCTION IN DISTINCT PATTERNS

THU0061

CORRELATIONS BETWEEN ANGIoGENIC FACTORS AND CAPILLAROSCOPIC PATTERNS IN SYSTEMIC SCLEROSIS

THU0062

THE POTENTIAL ROLE OF MAST CELLS IN THE C-PROTEIN INDUCED MYOSITIS MODEL

New drugs for lupus: state of the art

THU0055

Licensing new drugs in SLE: The EMA draft guideline

THU0056

Clinical trials in SLE: what have we learned?

THU0057

Biologics in lupus: which and for whom?

OP0129

EFFECTS OF BLIS/IMOD, AN INHIBITOR OF B-CELL ACTIVATING FACTOR, ON MARKERS OF RENAL DISEASE IN PATIENTS WITH SLE
**HOT Session 4**

**Speaker**
- Adami Silvano (Italy)
- Walsh David (United Kingdom)

**Abstract**
- OP0130: INDEPENDENT RISK FACTORS FOR CARDIOVASCULAR EVENTS IN MALE PATIENTS WITH GOUT: RESULTS OF THE 7-YEAR PROSPECTIVE FOLLOW-UP STUDY.
- OP0131: PREVALENCE AND PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN SYSTEMIC SCLEROSIS

---

**Clinical Science Session - Room N103/104**

**Nutrition and inflammation**

**Chair**
- Wittoek Ruth (Belgium)
- Khanna Dinesh (United States)

**Speaker**
- Hannan Marian T. (United States)
- Bischoff-Ferrari Heike A. (Switzerland)
- Choi Hyon K. (United States)

**Abstract**
- Barskova Victoria G. (Russian Federation): OP0130 - INDEPENDENT RISK FACTORS FOR CARDIOVASCULAR EVENTS IN MALE PATIENTS WITH GOUT: RESULTS OF THE 7-YEAR PROSPECTIVE FOLLOW-UP STUDY.
- Tauber Marie (France): OP0131 - PREVALENCE AND PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN SYSTEMIC SCLEROSIS

---

**Challenges in Clinical Practice Session - Hall 4**

**Difficult vasculitis - a difficult challenge**

**Chair**
- Mason Justin (United Kingdom)
- Terrier Benjamin (France)

**Presenter**
- Fanourakis Antonis (Greece)
- O’Neill Lorraine (Ireland)

**Case 1 presentation: B-cell depletion in vasculitis**
- Case 1 discussion: B-cell depletion in vasculitis

**Discussant**
- Vassilopoulos Dimitrios (Greece)
- Molloy Emeron S. (Ireland)

**Case 2 presentation: GCA and large vessel involvement**
- Case 2 discussion: GCA and large vessel involvement

---

**Outcomes Science Session - Room N101/102**

**Performance of RA remission criteria**

**Chair**
- van der Heim Annette (Netherlands)
- Carmona Loreto (Spain)

**Speaker**
- Allaart Renée (Netherlands)
- Gossec Laure (France)

**Abstract**
- Calhóf Johanna (Germany): OP0132 - REMISSION ACCORDING TO THE ACR/EULAR REMISSION CRITERIA IN PATIENTS WITH EARLY ARTHRITIS IS SIGNIFICANTLY INFLUENCED BY PATIENT-REPORTED FATIGUE AND WELL-BEING
- Castrejón Isabel (United States): OP0133 - ANALYSIS OF POTENTIAL PREDICTORS FOR REMISSION IN EARLY RHEUMATOID ARTHRITIS ACCORDING TO ACR/EULAR BOOLEAN, DAS28 AND RAPID3RI CRITERIA: RESULTS FROM THE ESPOIR COHORT
- Maymo J. (Spain): OP0134 - CUT-OFFS VALUES FOR INFLAMMATORY H-MRI LESIONS TO DEFINE REMISSION. COMPARISON BETWEEN DAS28, SDAI AND NEW BOOLEAN ACR/EULAR CRITERIA
- Aydin Sibel (Turkey): OP0135 - THE NEW ACR/EULAR CRITERIA FOR RHEUMATOID ARTHRITIS IS ABLE TO IDENTIFY PATIENTS WITH SAME DISEASE ACTIVITY BUT LESS DAMAGE BY ULTRASOUND

---

**Nutrition and osteoarthritis**

**Speaker**
- O'Neill Lorraine (Ireland)
- Vassilopoulos Dimitrios (Greece)

**Abstract**
- Case 2 discussion: GCA and large vessel involvement
- Case 2 presentation: GCA and large vessel involvement
### PReS Session - Room N105/106

#### Still’s disease

<table>
<thead>
<tr>
<th>Chair</th>
<th>Chair</th>
<th>Speaker</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wulfraat Nico (Netherlands)</td>
<td>Hofer Michael (Switzerland)</td>
<td>de Benedetti Fabrizio (Italy)</td>
<td>Pathophysiology of systemic JIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quarter Pierre (France)</td>
<td>Clinical pictures and outcome of systemic JIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rupert Nicola (Italy)</td>
<td>Novel therapeutic approaches for Still’s disease</td>
</tr>
<tr>
<td>Rupert N (Italy)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SP0068</th>
<th>Maes Christa (Belgium) Speaker</th>
<th>SP0069</th>
<th>Takayanagi Hiroshi (Japan) Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Primary Care Session - Room Retiro

#### Hot topics for primary care

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hay Elaine (United Kingdom)</td>
<td>OP0137-PC NUMBER OF PAINFUL REGIONS AND THEIR DISTRIBUTION PREDICTS OUTCOME OF PAIN IN THE GENERAL POPULATION</td>
</tr>
<tr>
<td>da Silva José Antonio P. (Portugal)</td>
<td>OP0064 Integrated approaches to long-term condition management in Primary Care</td>
</tr>
<tr>
<td>Mallen Christian D. (United Kingdom)</td>
<td>OP0138-PC HIGH PRESENCE OF CHRONIC DISEASES AT THE ONSET OF INFLAMMATORY ARTHRITIS: RESULTS FROM A POPULATION-BASED STUDY</td>
</tr>
</tbody>
</table>

### Basic and Translational Science Session - Room N107/108

#### Basics of skeletal muscle biology

<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lundberg Ingrid (Sweden)</td>
<td>Westerblad Hakan (Sweden)</td>
<td>SP0065 Inflammation and skeletal muscle: potential impact of rheumatic diseases on muscle function</td>
</tr>
<tr>
<td>Vencovsky Jiri (Czech Republic)</td>
<td>Glass David J. (United States)</td>
<td>SP0064 Molecular control of skeletal muscle homeostasis</td>
</tr>
<tr>
<td></td>
<td>Peterson Charlotte A (United States)</td>
<td>SP0066 Skeletal muscle repair: are satellite cells required?</td>
</tr>
<tr>
<td></td>
<td>Hamann Philip (United Kingdom)</td>
<td>OP0139 NEXT GENERATION SEQUENCING ANALYSIS OF THE TRANSCRIPTOME IN MUSCLE OBTAINED FROM ANTI-JO 1 POSITIVE IDIOPATHIC INFLAMMATORY MYOSITIS AND INCLUSION BODY MYOSITIS: A PILOT STUDY</td>
</tr>
</tbody>
</table>

### Basic and Translational Science Session - Room N109/110

#### Bone: a tale of cells and hormones

<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geusens Piet (Netherlands)</td>
<td>Takayanagi Hiroshi (Japan)</td>
<td>OP0067 Osteocytes and osteoclasts: crosstalk in osteoimmunology</td>
</tr>
<tr>
<td>Fearon Ursula (Ireland)</td>
<td>Maes Christa (Belgium)</td>
<td>OP0068 Osteoblasts in bone growth, homeostasis and repair</td>
</tr>
<tr>
<td></td>
<td>Yadav Vijay (United Kingdom)</td>
<td>OP0140 Bone regulation by the endocrine system</td>
</tr>
<tr>
<td></td>
<td>He Yi (Denmark)</td>
<td>OP0140 CIRCULATING CARBOXY-TERMINAL TYPE X COLLAGEN FRAGMENTS (C-COL10), A MEASURE OF SKELETAL HYPERTROPHY, ARE ELEVATED IN PATIENTS WITH OSTEOARTHRITIS AND ANKYLOSING SPONDYLITIS</td>
</tr>
<tr>
<td></td>
<td>Bleil Janine (Germany)</td>
<td>OP0141 NO SIGNS FOR DIRECT BONE FORMATION OR ENDOCONDRAL OSSIFICATION AT THE ENTHESES IN FACET JOINTS FROM</td>
</tr>
</tbody>
</table>
### Fellows in Training Session - Room N111/112

**ABC of science**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Catrina Anca</td>
<td>Sweden</td>
</tr>
<tr>
<td>Chair</td>
<td>Aleatha Daniel</td>
<td>Austria</td>
</tr>
<tr>
<td>Speaker</td>
<td>Symmons Deborah</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Speaker</td>
<td>Buckley Chris</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finding the right key for the right lock: choosing study design to answer research questions</td>
<td>SP0069</td>
</tr>
<tr>
<td>Choosing the right tool in the lab</td>
<td></td>
</tr>
</tbody>
</table>

### Health Professionals Session - Room N113/114

**The foot health needs of people with inflammatory arthritis in the era of biologic therapies**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Field Robert</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chair</td>
<td>Garcia Silvia</td>
<td>Spain</td>
</tr>
<tr>
<td>Speaker</td>
<td>Schulteobben Roswitha</td>
<td>Germany</td>
</tr>
<tr>
<td>Speaker</td>
<td>Edgson Lucy</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Speaker</td>
<td>Hooper Lindsey</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Speaker</td>
<td>Hendry Gordon</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The impact of foot issues experienced by people with inflammatory arthritis – a patient view</td>
<td>SP0070</td>
</tr>
<tr>
<td>Biologics therapies - changing the podiatry needs of people with inflammatory arthritis?</td>
<td>SP0071</td>
</tr>
<tr>
<td>The application of diagnostic ultrasound to the management of inflammatory arthritis – a foot and ankle perspective</td>
<td>SP0072</td>
</tr>
<tr>
<td>A new paradigm to managing the impact of inflammatory foot and ankle disease</td>
<td></td>
</tr>
</tbody>
</table>

### Practical Skills Session - Room N117

**MRI Basic 2**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Ostergaard Mikk</td>
<td>Denmark</td>
</tr>
<tr>
<td>Chair</td>
<td>Hermann Kay-Geert</td>
<td>Germany</td>
</tr>
<tr>
<td>Speaker</td>
<td>Ostergaard Mikk</td>
<td>Denmark</td>
</tr>
<tr>
<td>Speaker</td>
<td>Schueller-Weidekamm Claudia</td>
<td>Austria</td>
</tr>
<tr>
<td>Speaker</td>
<td>Hermann Kay-Geert</td>
<td>Germany</td>
</tr>
<tr>
<td>Speaker</td>
<td>Conaghan Philip</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis of RA and SpA using MRI</td>
<td>SP0040</td>
</tr>
<tr>
<td>Pitfalls in MRI in peripheral and inflammatory arthritis</td>
<td></td>
</tr>
<tr>
<td>MRI in psoriatic arthritis – from spine to toes</td>
<td></td>
</tr>
<tr>
<td>Case presentations: interaction and discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Practical Skills Session - Room N118

**Dealing with journalists - media training by media professionals**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>van de Putte Leo</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Speaker</td>
<td>Chapman Christine</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Speaker</td>
<td>Abdalla Rawaa</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Speaker</td>
<td>van de Putte Leo</td>
<td>Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The WHAT and WHY of media activity</td>
<td></td>
</tr>
<tr>
<td>The audience - Key messages - Interview skills</td>
<td></td>
</tr>
<tr>
<td>Open floor Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### Practical Skills Session - Room N115

**Crystals in synovial fluid 2**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Bardin Thomas</td>
<td>France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PARE Session - Room N116

Patient rights to crossborder healthcare and other entitlements

Chair Grygielska Jolanta (Poland)
Chair Greiff Roll (Sweden)
Speaker Chaze Nathalie (Belgium) The directive on patients’ rights for cross-border healthcare - an EU perspective
Speaker Faubel Ursula (Germany) Lobbying for a bill of patient rights
Speaker Svanberg Beryl (Sweden) SP0075 “Patient school” – a Swedish case study to empower people with RMDs
Abstract Betteridge Kate (United Kingdom) OP0143-PARE IMPROVING PATIENT EXPERIENCE IN ENHANCED RECOVERY AFTER SURGERY
Abstract Sellam Jeremie (France) OP0144-PARE INVOLVEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN THE CHOICE OF THEIR TREATMENT: SURVEY CONDUCTED IN FRANCE AMONG A SAMPLE OF PATIENTS BELONGING TO AN ASSOCIATION OF PATIENTS

Thursday 13.06.2013 15:30 - 17:00

What is New (WIN) - Hall 6

WIN Session 4
Speaker van Vollenhoven Ronald (Sweden) SP0076 SLE and APS
Speaker Salvarani Carlo (Italy) SP0077 Vasculitis

Clinical Science Session - Hall 8

Modern assessment of disease activity in inflammatory arthritis
Chair Maksmowych Walter (Canada)
Chair Juhl Pedersen Susanne (Denmark)
Speaker Backhaus Marina (Germany) SP0078 New imaging approaches for detecting arthritis
Speaker Taylor Peter C. (United Kingdom) Serum biomarker combinations for assessment of RA
Speaker Kirwan John R (United Kingdom) Assessment of inflammation - lessons from the patient

How to Treat / Manage (HOT) - Hall 7

HOT Session 5
Speaker Kallenberg Cees G.M. (Netherlands) Vasculitis
Speaker van Laar Jacob M. (United Kingdom) Raynaud’s phenomenon and Systemic sclerosis

Clinical Science Session - Room N103/104

Impact of imaging on clinical practice
<table>
<thead>
<tr>
<th>Chair</th>
<th>Aydin Sibel Zehra (Turkey)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Möller Ingrid (Spain)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Terslev Lene (Denmark)</td>
</tr>
<tr>
<td>Abstract</td>
<td>COMEC Divi (France)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Conaghan Philip (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td></td>
</tr>
<tr>
<td>Speaker</td>
<td>Ostergaard Mikkel (Denmark)</td>
</tr>
<tr>
<td>Abstract</td>
<td></td>
</tr>
<tr>
<td>Speaker</td>
<td>Condon Mike (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td></td>
</tr>
<tr>
<td>Speaker</td>
<td>Bestariung (China)</td>
</tr>
<tr>
<td>Abstract</td>
<td></td>
</tr>
</tbody>
</table>

**Challenges in Clinical Practice Session - Hall 4**

**Peripheral neuropathy in rheumatic diseases**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Toloza Sergio (Argentina)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Castellvi Ivan (Spain)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Peteren Hel (Germany)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Lee Yvonne (United States)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Blaes Franz (Germany)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Syngle Ashit (India)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Peredo Ruben (United States)</td>
</tr>
</tbody>
</table>

**Outcomes Science Session - Room N101/102**

**Investigating in a world of confounders**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Ospelt Caroline (Switzerland)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Massardo Loreto (Chile)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Alfredsson Lars (Sweden)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Svensson Bjar (Sweden)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Verstappen Suzanne (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Orelana Cecilia (Sweden)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Castrejon Isabel (United States)</td>
</tr>
</tbody>
</table>

**Primary Care Session - Room Retiro**

**Life-long management of rheumatic diseases**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Damen Jurgen (Netherlands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Dagfinrud Harne (Norway)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Bergman Stefan (Sweden)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Hakkinen Arja Helena (Finland)</td>
</tr>
</tbody>
</table>

---

For the full schedule, please visit http://81.63.133.217/EULAR%20Production/2013_Madrid.nsf/fmWebPGMbyDayPublic?OpenForm

31.05.2013
Basic and Translational Science Session - Room N107/108

**Tissue repair by DMOADs: the proof of the pudding**

- **Chair**: Kloopenburg Margreet (Netherlands)
- **Chair**: Mastbergen Simon (Netherlands)
- **Speaker**: Javaid Muhammad Kassim (United Kingdom) - The mechanisms behind DMOAD activity of strontium ranelate
- **Speaker**: Karsdal Morten (Denmark) - Evidence for DMOAD activity of salmon calcitonin, in vitro and animal in vivo studies
- **Speaker**: Ladel Christoph (Germany) - Pre-clinical proof for DMOAD activity of FGF-18
- **Abstract**: Roemer Frank (Germany) - Subchondral bone marrow lesions predict incident radiographic osteoarthritis
- **Abstract**: Abou-Raya Suzan (Egypt) - Chemerin and knee osteoarthritis: effects on inflammation and cartilage destruction

Basic and Translational Science Session - Room N109/110

**Translational model of fibrosis and myositis**

- **Chair**: Beyer Christian (Germany)
- **Chair**: Czirjak László (Hungary)
- **Speaker**: Distler Jörg (Germany) - Fibrotic disease models
- **Speaker**: Maurer Britta (Switzerland) - Vascular disease models in SSc
- **Speaker**: Nagaraju Kannepoyina (United States) - Animal models of myositis
- **Abstract**: Leask Andrew (Canada) - A novel model of systemic sclerosis: loss of PTEN in fibroblasts results in lung fibrosis in a CCN2/CTGF-dependent fashion
- **Abstract**: Dees Clara (Germany) - Epigenetic silencing of endogenous WNT inhibitors contributes to the aberrant activation of canonical WNT signaling in systemic sclerosis

Fellows in Training Session - Room N111/112

**Finding the truth in medical literature: how to read clinical journals?**

- **Chair**: Moorts Robert (United Kingdom)
- **Chair**: Castrejon Isabel (Spain)
- **Speaker**: Carmona Loreto (Spain) - Deciding which journals to read regularly: How to manage one’s way through the medical information jungle without getting lost or eaten alive?
- **Speaker**: Boers Maarten (Netherlands) - Using literature to solve clinical problems
- **Speaker**: Moorts Robert (United Kingdom) - Interactive discussion
- **Speaker**: Moderators (-) - Interactive discussion

Joint Clinical / HPR / PARE Session - Room N113/114
### The concept of health in rheumatic disease: the ability to adapt and self-manage

<table>
<thead>
<tr>
<th>Chair</th>
<th>Geenen Rinie (Netherlands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker</td>
<td>Boonen Arnettes (Netherlands)</td>
</tr>
<tr>
<td>SP0094</td>
<td>The role of personal and psychological factors on the experience of health in patients with arthritis: frameworks and evidence</td>
</tr>
<tr>
<td>Speaker</td>
<td>Taylor Julie (United Kingdom)</td>
</tr>
<tr>
<td>SP0095</td>
<td>Coping as integral to understanding and assessing health and well-being in rheumatoid arthritis</td>
</tr>
<tr>
<td>Speaker</td>
<td>Geenen Rinie (Netherlands)</td>
</tr>
<tr>
<td>SP0096</td>
<td>Promoting awareness and the ability to adapt and self-manage the conditions to improve the suitability of work in fibromyalgia</td>
</tr>
<tr>
<td>Speaker</td>
<td>Collins Sarah (United Kingdom)</td>
</tr>
<tr>
<td>SP0097</td>
<td>How can I still be Me?</td>
</tr>
</tbody>
</table>

### Practical Skills Session - Room N117

#### Ultrasound Advanced 1

<table>
<thead>
<tr>
<th>Chair</th>
<th>Schmidt Wolfgang A. (Germany)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Naredo Esperanza (Spain)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Gargani Luna (Italy)</td>
</tr>
<tr>
<td>SP0098</td>
<td>Ultrasound in lung fibrosis</td>
</tr>
<tr>
<td>Speaker</td>
<td>Bianchi Stefano (Switzerland)</td>
</tr>
<tr>
<td>SP0099</td>
<td>Ultrasound in trauma - what the rheumatologist needs to know</td>
</tr>
<tr>
<td>Speaker</td>
<td>Schmidt Wolfgang A. (Germany)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Naredo Esperanza (Spain)</td>
</tr>
<tr>
<td>SP0094</td>
<td>The practical case: pitfalls for ultrasound in vasculitis - live case with patient</td>
</tr>
<tr>
<td>SP0095</td>
<td>Hands-on scanning in groups with patients with traumatic lesions OR Quiz</td>
</tr>
</tbody>
</table>

### EULAR Projects in Paediatric Rheumatology - Room N118

#### The challenges of PReS today

<table>
<thead>
<tr>
<th>Chair</th>
<th>Calvo Inmaculada (Spain)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Zulian Francesco (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Martini Alberto (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Prakken Berent J. (Netherlands)</td>
</tr>
<tr>
<td>SP0100</td>
<td>Networking in basic research</td>
</tr>
<tr>
<td>Speaker</td>
<td>Russo Ricardo (Argentina)</td>
</tr>
<tr>
<td>SP0101</td>
<td>Paediatric rheumatology in South America</td>
</tr>
<tr>
<td>Abstract</td>
<td>Homeff Gerd (Germany)</td>
</tr>
<tr>
<td>OP0157</td>
<td>USE OF BIOLOGICS IN PATIENT WITH JUVENILE IDIOPATHIC ARTHRITIS</td>
</tr>
</tbody>
</table>

### Practical Skills Session - Room N115

#### ABCs of biopsies: when to perform and how to interpret

<table>
<thead>
<tr>
<th>Chair</th>
<th>Machado Pedro (Portugal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Mandl Peter (Austria)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Baeten Dominique (Netherlands)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Lundberg Ingrid (Sweden)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Kruize Aike (Netherlands)</td>
</tr>
<tr>
<td>SP0102</td>
<td>Synovial biopsy</td>
</tr>
<tr>
<td>SP0101</td>
<td>Muscular biopsy</td>
</tr>
<tr>
<td>SP0102</td>
<td>Labial biopsy</td>
</tr>
</tbody>
</table>

### PARE Session - Room N116

#### Gender differences in care and treatment

<table>
<thead>
<tr>
<th>Chair</th>
<th>Wiek Dieter (Germany)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Bozhinova Sreznaha (Bulgaria)</td>
</tr>
</tbody>
</table>
Friday 14.06.2013 08:15 - 09:45
Basic and Translational Science Session - Room N109/110

**Macrophage biology in inflammation**
- **Chair:** Perretti Mauro (United Kingdom)
- **Chair:** Bégini Stephan (Austria)
- **Speaker:** Mantovani Alberto (Italy) - Biologic and functional aspects of macrophages
- **Speaker:** Gilroy Derek (United Kingdom) - The 'resolving macrophage'
- **Speaker:** Ariel Amiram (Israel) - Macrophages, meta-inflammation and tissue remodelling
- **Abstract:** Degbô Yannick (France) - MONOCYTE AND DENDRITIC CELL ACTIVATION VIA TLR4; ANTI-INFLAMMATORY MODULATION BY DENDRIMER ABP

Friday 14.06.2013 10:15 - 11:45
Basic and Translational Science Session - Room N113/114

**Novel technologies: ready to contribute to rheumatic diseases**
- **Chair:** Apparailly Florence (France)
- **Chair:** van der Woude Diane (Netherlands)
- **Speaker:** Ruiz-Romero Cristina (Spain) - Proteomics: a long way from protein extract towards clinical applications: lessons from osteoarthritis
- **Speaker:** Malaffi Fransiska (Belgium) - Next Generation Sequencing and related technologies, a way forward for arthritis? Lessons from connective tissue disorders
- **Speaker:** Bay-Jenssen Anne-Christine (Denmark) - Biomarkers: how to find and develop novel and biologically relevant candidates?
- **Speaker:** Brayden David (Ireland) - Nanomedicine: innovate drug delivery

Friday 14.06.2013 08:15 - 09:45
What is New (WIN) - Hall 6

**WIN Session 5**
- **Speaker:** Bootsma Hendrika (Netherlands) - Sjögren's Syndrome
- **Speaker:** Pascual Gomez Eliseo (Spain) - Gout and crystal diseases

**Abstract Session - Hall 8**

**Abstract session: Cardiovascular and other co-morbidities in patients with rheumatoid arthritis**
- **Chair:** Nurmohamed Michael (Netherlands)
- **Chair:** Bugatti Serena (Italy)
- **Abstract:** Gladue Heather (United States) - EVALUATION OF NON-INVASIVE TESTS AS AN EARLY DIAGNOSTIC SCREEN FOR PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS
- **Abstract:** Lillegren Sri (Norway) - USE OF TNF INHIBITORS IS ASSOCIATED WITH A REDUCED RISK OF DIABETES IN RA PATIENTS
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Author</th>
<th>Code</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Grog Katherine (Denmark)</td>
<td>OP0162</td>
<td>PREVALENCE OF COMORBIDITIES IN RHEUMATOID ARTHRITIS. DOES GROSS DOMESTIC PRODUCT MATTER? RESULTS FROM 34 COUNTRIES IN THE QUEST-RA PROGRAM</td>
</tr>
<tr>
<td>2.</td>
<td>Winthrop K (United States)</td>
<td>OP0163</td>
<td>EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINE RESPONSES IN RHEUMATOID ARTHRITIS PATIENTS USING TOFACITINIB</td>
</tr>
<tr>
<td>3.</td>
<td>Myasoedova Elena (United States)</td>
<td>OP0164</td>
<td>LONG-TERM BLOOD PRESSURE VARIABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) VS GENERAL POPULATION, AND ITS IMPACT ON CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY IN RA</td>
</tr>
<tr>
<td>4.</td>
<td>Dessein Patrick (South Africa)</td>
<td>OP0165</td>
<td>RHEUMATOID ARTHRITIS IS ASSOCIATED WITH REDUCED ADIPOSY BUT NOT WITH UNFAVORABLE MAJOR CARDIOVASCULAR RISK FACTOR PROFILES AND ENHANCED CAROTID ATHEROSCLEROSIS IN BLACK AFRICANS FROM A DEVELOPING POPULATION: A CASE-CONTROL STUDY</td>
</tr>
<tr>
<td>5.</td>
<td>Van Sijl Alper (Netherlands)</td>
<td>OP0166</td>
<td>SUSTAINED DEVELOPMENT OF CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS DESPITE CARDIOPROTECTIVE TREATMENT: THE 10-YEAR PROSPECTIVE CARRE-STUDY</td>
</tr>
<tr>
<td>6.</td>
<td>Meissner Yvette (Germany)</td>
<td>OP0167</td>
<td>ACUTE MYOCARDIAL INFARCTION IS DRIVEN BY CHRONIC SYSTEMIC INFLAMMATION, IRRESPECTIVE OF THE KIND OF TREATMENT - DATA FROM THE GERMAN BIOLOGICS REGISTER RABBIT</td>
</tr>
</tbody>
</table>

**How to Treat / Manage (HOT) - Hall 7**

**HOT Session 6**

- **Speaker**: da Silva José Antonio P. (Portugal)
- **Abstract**: Imaging in diagnosis of rheumatic diseases
- **Chair**: Gandjbakhch Frédérique (France)
  - **Abstract**: Fibromyalgia
  - **Abstract**: Juvenile idiopathic arthritis JIA and other paediatric diseases

**Abstract Session - Room N103/104**

**Abstract session: Imaging in diagnosis of rheumatic diseases**

- **Chair**: Handl Peter (Austria)
- **Chair**: Gandjbakhch Frédérique (France)
- **Abstract**: Musetescu Anca Emanuela (Romania) | OP0168 | ULTRASOUND MORPHOSTRUCTURAL CHANGES IN HYPERURICEMIC HYPERTENSIVE PATIENTS ASYMPTOMATIC FOR GOUTY ARTHRITIS |
- **Abstract**: Skeoch Sarah (United Kingdom) | OP0169 | ASSESSMENT OF LUPUS NEPHRITIS DISEASE ACTIVITY USING NON-CONTRAST MRI: A PILOT STUDY |
- **Abstract**: Hammer Hilde (Norway) | OP0170 | THE RADIOCARPAL AND MCP2 JOINTS SHOULD BE INCLUDED IN ULTRASONOGRAPHIC FOLLOW-UP OF RA PATIENTS DURING BIOLOGIC TREATMENT |
- **Abstract**: Haj Hensvold Aase (Sweden) | OP0171 | SCREENING FOR ANTI-CCP IN A LARGE POPULATION BASED COHORT AND ITS ASSOCIATION WITH PREVALENT RHEUMATOID ARTHRITIS |
- **Abstract**: Bertoli Ana (Argentina) | OP0172 | THE PRESENCE AND INTENSITY OF POWER DOPPLER SIGNAL ARE NOT MODIFIED BY TIME OF ASSESSMENT: DATA FORM PATIENTS WITH RHEUMATOID ARTHRITIS |
- **Abstract**: Krabben Annemarie (Netherlands) | OP0173 | CONCORDANCE BETWEEN JOINT SWELLING OR TENDERNESS AT PHYSICAL EXAMINATION AND INFLAMMATION ON MRI IN EARLY ARTHRITIS PATIENTS |
- **Abstract**: Aga Anna-Birgitte (Norway) | OP0174 | ULTRASONOGRAPHIC FINDINGS IN AN INCEPTION COHORT OF 175 DMARD NAÏVE RHEUMATOID ARTHRITIS PATIENTS |
- **Abstract**: Gandjbakhch Frederique (France) | OP0175 | SYSTEMIC LUPUS ERYTHEMATOSUS AND PRIMARY SJOGREN'S SYNDROME MAY DISPLAY JOINT EROSIONS ON MRI AS WELL AS HEALTHY CONTROL, BUT CANNOT BE CONSIDERED AS EROSIve DISEASE SUCH AS RHEUMATOID ARTHRITIS: AN MRI OBSERVATIONAL STUDY OF 90 SUBJECTS |

**Abstract Session - Hall 4**

**Abstract session: RA - prognosis, predictors and outcome**

- **Chair**: Castelar Geraldo (Brazil)
- **Chair**: Araujo Elizabeth (Germany)
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Author(s)</th>
<th>OP Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>Rantapää Dahiqivist Solbritt (Sweden)</td>
<td>OP0176</td>
</tr>
<tr>
<td>Abstract</td>
<td>De Jong Pascal (Netherlands)</td>
<td>OP0177</td>
</tr>
<tr>
<td>Abstract</td>
<td>Greneese Elisa (Italy)</td>
<td>OP0178</td>
</tr>
<tr>
<td>Abstract</td>
<td>De Rooy Diedenik (Netherlands)</td>
<td>OP0179</td>
</tr>
<tr>
<td>Abstract</td>
<td>Raiekh Chadi (United Kingdom)</td>
<td>OP0180</td>
</tr>
<tr>
<td>Abstract</td>
<td>De Winter Liesbeth (Belgium)</td>
<td>OP0181</td>
</tr>
<tr>
<td>Abstract</td>
<td>Wevers-De Boer Kirsten (Netherlands)</td>
<td>OP0182</td>
</tr>
<tr>
<td>Abstract</td>
<td>Van Nies Jessica (Netherlands)</td>
<td>OP0183</td>
</tr>
</tbody>
</table>

**Abstract Session - Room N101/102**

**Abstract session: Pathogenesis of RA: new clues?**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Pisetsky David S. (United States)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Scali Juan Jose (Argentina)</td>
</tr>
<tr>
<td>Abstract</td>
<td>de Garavilla Lawrence (United States)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Gjerlsnes Inger (Sweden)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Seror Raphaelé (France)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Suzuki Miho (Japan)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Ducreux Julie (Belgium)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Scherer Hans (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>van der Woude Diane (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Maeda Yuichi (Japan)</td>
</tr>
</tbody>
</table>

**Abstract Session - Room N105/106**

**Abstract Session: Innate and adaptive immunity**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Bombarderi Michele (United Kingdom)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Böhm Stephan (Austria)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Gadola Stephan (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Spengler Julia (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Terrier Benjamin (France)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Oravecz Tamas (United States)</td>
</tr>
</tbody>
</table>
INFLAMMATORY/ANGIOGENIC MECHANISMS IN GCA TEMPORAL ARTERY EXPLANT CULTURES EX VIVO.


Introduction

STEP-UP: AN INNOVATIVE STEPPED-CARE PROTOCOL FOR TAILORED BEHAVIORAL MEDICINE TREATMENT IN THE MANAGEMENT OF MUSCULOSKELETAL PAIN IN PRIMARY CARE

AGREEMENT OF GENERAL PRACTITIONERS WITH THE GUIDELINE-BASED STEPPED-CARE STRATEGY FOR PATIENTS WITH A HIGH RISK OF ADVERSE DRUG EVENTS

MULTISITE PERIPHERAL JOINT PAIN IN THE COMMUNITY: PREVALENCE AND IMPACT IN THE NORTH WEST MIDLANDS, UNITED KINGDOM (UK)

ASSESSING RISK OF FRACTURE IN PRIMARY CARE: FRAX AND QFRACTURE

Abstract Session Primary Care: From epidemiology to effective practice

Abstract Session - Room Retiro

Abstract Primary Care: From epidemiology to effective practice

Abstract - Room N107/108

Abstract Session: Novel advances in vasculitis: pathogenesis, diagnosis and treatment

Abstract - Room N107/108

Abstract - Room Retiro

Abstract - Room N107/108
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Terrier Benjamin (France)</th>
<th>OP0213</th>
<th>RITUXIMAB VERSUS AZATHIOPRINE FOR MAINTENANCE IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA)-ASSOCIATED VASCULITIS (MAINRTS): FOLLOW UP AT 34 MONTHS.</th>
</tr>
</thead>
</table>

**Abstract Session - Room N109/110**

**Abstract session: Spondyloarthrosis - diagnosis and prognosis**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Weber Ulrich (Switzerland)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Poddubny Denis (Germany)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Kiltz Uta (Germany)</th>
<th>OP0214</th>
<th>DEVELOPMENT OF A HEALTH INDEX IN PATIENTS WITH ANKYLOSING SPONDYLITIS (ASAS H)? FINAL RESULT OF A GLOBAL INITIATIVE BASED ON THE ICF GUIDED BY ASAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>Berg Inger Jorid (Norway)</td>
<td>OP0215</td>
<td>BASELINE ASDAS AND CRP PREDICTS FUTURE CARDIOVASCULAR RISK IN ANKYLOSING SPONDYLITIS: RESULTS AFTER 5-YEAR FOLLOW-UP</td>
</tr>
<tr>
<td>Abstract</td>
<td>Weber Ulrich (Switzerland)</td>
<td>OP0216</td>
<td>ELEVATED SERUM LEVEL OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR PREDICTS RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Ramiro Sofia (Netherlands)</td>
<td>OP0217</td>
<td>FREQUENT DETECTION OF INFLAMMATION AND FAT INfiltrATION SUGGESTIVE OF SPONDYLOARTHRITIS ON MRI OF THE ENTIRE SPINE IN HEALTHY SUBJECTS AND PATIENTS WITH MECHANICAL BACK PAIN</td>
</tr>
<tr>
<td>Abstract</td>
<td>Briot Karine (France)</td>
<td>OP0218</td>
<td>EROSIONS AND SCLEROSIS, BUT NOT SQURING PREDICT THE DEVELOPMENT OF NEW SYENDESMOPHYTES: A 12-YEAR LONGITUDINAL ANALYSIS</td>
</tr>
</tbody>
</table>

**Abstract Session - Room N111/112**

**Abstract session: Systemic sclerosis, which pathway is really important?**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Lambova Sevdalina (Bulgaria)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Vasilis Massimiliano (Italy)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Manetti Mirko (Italy)</th>
<th>OP0222</th>
<th>INACTIVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR INDUCES DERMAL AND PULMONARY FIBROSIS AND PERIPHERAL MICROVASCULOPATHY IN MICE CLOSELY RESEMBLING HUMAN SYSTEMIC SCLEROSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>Zhang Yun (Germany)</td>
<td>OP0223</td>
<td>INHIBITION OF CASEIN KINASE-2 ALLEVIATES THE PROFIBROTIC EFFECTS OF TRANSFORMING GROWTH FACTOR ? IN SYSTEMIC SCLEROSIS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Kill Angela (Germany)</td>
<td>OP0224</td>
<td>ANTI-AT1R AND ANTI-ETAR AUTOANTIBODIES FROM PATIENTS WITH SSC AND THEIR AGONISTIC EFFECTS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Rossato Marzia (Netherlands)</td>
<td>OP0225</td>
<td>MICRONAS UNDERLIE PLASMACYTOID DENDRITIC CELL DYSFUNCTION IN SYSTEMIC SCLEROSIS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Spadoni Tatiana (Italy)</td>
<td>OP0226</td>
<td>WIPI, A WNT PATHWAY INHIBITOR, IS SILENCED IN SYSTEMIC SCLEROSIS BY DNA DAMAGE: A MECHANISM LINKING DNA DAMAGE TO WNT AND FIBROSIS.</td>
</tr>
<tr>
<td>Abstract</td>
<td>Avouac Jerome (France)</td>
<td>OP0227</td>
<td>CRITICAL ROLE OF THE ADHESION RECEPTOR DNA ACCESSORY MOLECULE-1 (DANM-1) IN THE DEVELOPMENT OF INFLAMMATION-DRIVEN DERMAL FIBROSIS IN MOUSE MODEL OF SYSTEMIC SCLEROSIS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Distler Oliver (Switzerland)</td>
<td>OP0228</td>
<td>PROTECTIVE EFFECT OF LPA1 AND 3 RECEPTOR ANTAGONISM IN EXPERIMENTAL SKIN FIBROSIS IS LINKED TO LPA ACTIVITY IN DERMAL FIBROBLASTS OF SSC PATIENTS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Iwamoto Naoki (Switzerland)</td>
<td>OP0229</td>
<td>MIR-193B INDUCES UPA IN SSC AND CONTRIBUTES TO THE Proliferative Vasculopathy VIA UPAR INDEPENDENT PATHWAYS</td>
</tr>
</tbody>
</table>

**Abstract Session - Room N113/114**
Abstract Session HPR: Making progress in clinical practice

Chair: Cornell Patricia (United Kingdom)

Chair: Prior Yeliz (United Kingdom)

Abstract: Stanmore Emma (United Kingdom) OP0230-HPR
FALLS, FEAR OF FALLING AND RISK FACTORS IN ADULTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY

Abstract: Oude Voshaar Martijn (Netherlands) OP0231-HPR
PREDICTORS OF NO IMPROVEMENT IN SUBJECTIVE HEALTH PERCEPTION IN NEWLY DIAGNOSED RA PATIENTS WITH A GOOD DAS28 RESPONSE AT 12 MONTHS IN THE DREAM TIGHT CONTROL COHORT.

Abstract: Macfarlane Gary (United Kingdom) OP0232
LONG-TERM EFFECTS OF COGNITIVE BEHAVIOUR THERAPY AND EXERCISE FOR CHRONIC WIDESPREAD PAIN

Abstract: Meier A. J. L (Netherlands) OP0233-HPR
THE FEASIBILITY OF THE USE OF PATIENT-DERIVED JOINT COUNTS IN TREAT-TO-TARGET STRATEGIES IN RHEUMATOID ARTHRITIS

Abstract: Soubrier M. (France) OP0234
IMPACT OF A NURSE LED PROGRAM ON THE MANAGEMENT OF COMORBIDITIES IN RHEUMATOID ARTHRITIS (RA). RESULTS OF A PROSPECTIVE, MULTICENTRE, RANDOMIZED, CONTROLLED TRIAL (COMEDRA)

Abstract: Larsen Janri (Denmark) OP0235-HPR
TARGETED INFORMATION ON METHOTREXATE AND LIFTING ALCOHOL RESTRICTIONS IN PATIENTS WITH RA AND PSA IS SAFE AND REDUCES PATIENTS' NEGATIVE BELIEFS

Abstract: White Jo (United Kingdom) OP0236-HPR
THE IMPLEMENTATION OF A NOVEL SOFTWARE APPLICATION (MIDATABANK) TO RECORD, TRIAGE AND MANAGE TELEPHONE CALLS TO THE LEEDS RHEUMATOLOGY OUTPATIENT'S DEPARTMENT

Abstract: Manning Victoria (United Kingdom) OP0237-HPR
UPPER LIMB EXERCISE, EDUCATION AND SELF MANAGEMENT IN EARLY RHEUMATOID ARTHRITIS (THE EXTRA PROGRAMME): RESULTS FROM A RANDOMISED CONTROLLED TRIAL

Abstract Session - Room N117

Abstract session: Cells, molecules and markers in spondyloarthritis

Chair: Baeten Dominique (Netherlands)

Chair: Lambrecht Stijn (Belgium)

Abstract: Milling Simon (United Kingdom) OP0238
PATIENTS WITH ANKYLOSING SPONDYLITIS HAVE AN INCREASED PROPORTION OF CD16+ DENDRITIC CELLS, ABLE TO INDUCE CCR6-EXPRESSION ON CD4+ T CELLS

Abstract: Hreggvidsdottir Hulda (Netherlands) OP0239
PHENOTYPIC AND MOLECULAR PROFILE OF INNATE LYMPHOID CELLS IN CHRONIC SYNOVIAL INFLAMMATION

Abstract: Wallis Dinny (Canada) OP0240
HIGHER EXPRESSION OF TNFR1 AND IL-1R2 ON CELL SURFACE OF B'2705 ANKYLOSING SPONDYLITIS PATIENTS VS B'2705 AND B'2709 HEALTHY SUBJECTS. INFLUENCE OF ERAP1 POLYMORPHISM

Abstract: Filippopoulou Alexandra (Greece) OP0241
ANTIFLAGELLIN ANTIBODIES IN ANKYLOSING SPONDYLITIS (AS) IMPLICATE SUBCLINICAL BOWEL INFLAMMATION AND DIFFERENTIATE AS FROM MECHANICAL BACK PAIN PATIENTS.

Abstract: Magrey Marina (United States) OP0242
SERUM INDIAN HEDGEHOG (IHH) LEVELS ARE INCREASED IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS). ANTI-TNF? TREATMENT DECREASES SERUM IHH LEVELS IN PATIENTS WITH AS AND AFFECTS THE EXPRESSION OF FUNCTIONAL TARGET GENES IN A CELL LINE MODEL

Abstract: Blei Janine (Germany) OP0243
MICRORNA EXPRESSION PROFILE IN PATIENTS WITH SPONDYLOARTHITIS: A PILOT STUDY

Abstract: Cauli Alberto (Italy) OP0244
HIGH EXPRESSION OF PROSTAGLANDIN E2 IN ZYGAPHERESEAL JOINTS OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND OSTEOARTHRITIS

Abstract Session - Room N118

Abstract session: Osteoporosis

Chair: Adami Silvano (Italy)

Chair: Geusens Piet (Netherlands)

Abstract: Ochi Kensuke (Japan) OP0245
SITES, FREQUENCIES, AND CAUSES OF FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A LARGE PROSPECTIVE OBSERVATIONAL COHORT STUDY IN JAPAN
| Abstract | Bullink Irene (Netherlands) | OP0246 | INCIDENCE OF AND RISK FACTORS FOR CLINICAL FRACTURES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND MATCHED CONTROLS: A POPULATION-BASED STUDY IN THE UNITED KINGDOM |
| Abstract | Palacios Santiago (Spain) | OP0247 | EFFECTS OF ODANACATIB ON BMD AND SAFETY IN THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PREVIOUSLY TREATED WITH ALENDRONATE? A RANDOMIZED PLACEBO-CONTROLLED TRIAL |
| Abstract | Brown J (Canada) | OP0248 | INHIBITION OF SCLEROSTIN WITH ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY: PHASE 2 TRIAL RESULTS |
| Abstract | Evstigneyeva Lyudmila (Russian Federation) | OP0249 | EFFECT OF EXERCISE FOR PATIENT WITH OSTEOPOROTIC VERTEBRAL FRACTURES |
| Abstract | Roux C (France) | OP0250 | DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FOR 7 YEARS: CLINICAL FRACTURE RESULTS FROM THE FIRST 4 YEARS OF THE FREEDOM EXTENSION |
| Abstract | Zerbini Cristiano (Brazil) | OP0251 | BONE HISTOLOGY AND HISTOMORPHOMETRY: EFFECTS OF 5 YEARS OF DENOSUMAB IN THE FREEDOM STUDY EXTENSION |
| Abstract | Xu Ting (China) | OP0252 | EFFECT OF GLUCOCORTICOIDS AND BISPHOSPHONATES ON PPARGAMMA AND HEDGEHOG PATHWAY IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS |

**Abstract Session - Room N115**

**Abstract session: Unravelling inflammatory pathways**

| Chair | Radstake Timothy R. (Netherlands) |
| Chair | Hueber Axel (Germany) |
| Abstract | Boyle David (United States) | OP0253 | THE JAK INHIBITOR TOFACITINIB SUPPRESSES SYNOVIAL JAK1-STAT1 SIGNALLING IN RHEUMATOID ARTHRITIS |
| Abstract | Grabiec Aleksander (Netherlands) | OP0254 | CYTOKINE-INDUCED JNK-DEPENDENT DOWNREGULATION OF THE FORKHEAD BOX Q TRANSCRIPTION FACTOR FOXO1 PROMOTES SURVIVAL AND PROLIFERATION OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS |
| Abstract | Streicher Katie (United States) | OP0255 | INHIBITION OF THE PLASMA CELL SIGNATURE CORRELATES WITH REDUCED COLLAGEN EXPRESSION IN SYSTEMIC SCLEROSIS |
| Abstract | Engler Anna (Switzerland) | OP0256 | SIRT1 REGULATES CIGARETTE SMOKE-INDUCED IL8 EXPRESSION AND TNF?-MEDIATED IL6 RELEASE IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS |
| Abstract | Balogh Emese (Ireland) | OP0257 | INTERLEUKIN-34 REGULATES ANGIOGENESIS AND CELL PROLIFERATION IN INFLAMMATORY ARTHRITIS |
| Abstract | Nayar Saba (United Kingdom) | OP0258 | IL-22 REGULATES LYMPHOID STROMAL CELL EXPANSION, DEVELOPMENT OF GERMINAL CENTERS AND HUMORAL RESPONSE IN MUCOSAL ECCTOPIC LYMPHONEOGENESIS |
| Abstract | Millar Neal (United Kingdom) | OP0259 | THE INTERLEUKIN 33/MIR29 AXIS REGULATES DIFFERENTIAL COLLAGEN PRODUCTION IN TENDINOPATHY |
| Abstract | Hillen Maarten (Netherlands) | OP0260 | TARGETING CD1C-EXPRESSING MDCS TO INHIBIT T CELL ACTIVATION AND THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC)-DEPENDENT CHEMOTAXIS IN RA |

**Abstract Session - Room N116**

**Abstract Session PARE: From abstract to concrete - the variety of activities in the PARE organisations**

| Chair | Betteridge Kate (United Kingdom) |
| Chair | Faubel Ursula (Germany) |
| Abstract | Bosworth Alisa (United Kingdom) | OP0261-PARE | WHAT IS REMISSION TO YOU? DEFINING REMISSION FROM THE PATIENT’S PERSPECTIVE IN RHEUMATOID ARTHRITIS |
| Abstract | Garrido-Castro Juan L. (Spain) | OP0262-PARE | WHAT IS THE KNOWLEDGE LEVEL THAT ANKYLOSING SPONDYLITIS PATIENTS HAVE ABOUT THEIR OWN DISEASE? |
| Abstract | van Duijn Henk (Netherlands) | OP0263-PARE | PATIENT INVOLVEMENT IN E-HEALTH RESEARCH AND INTERVENTION DEVELOPMENT |
| Abstract | Bozhinova Snehana (Bulgaria) | OP0264-PARE | ‘WITH LOVE AND SMILE’ - CHARITY EVENTS FOR PEOPLE WITH RHEUMATIC DISEASES |
| Abstract | Carlsson Anne (Sweden) | OP0265-PARE | NATIONAL GUIDELINES FOR MUSCULOSKELETAL DISEASES IN SWEDEN |
| Abstract | Udrais Enid (Estonia) | OP0266-PARE | OSTEOPOROSIS PREVENTION PROJECT IN ESTONIA: BONE DENSITY MEASUREMENTS, PATIENT COUNSELING, INFORMATION DAYS, LECTURES AND MATERIALS |
N-TERMINAL PRO-PEPTIDE (PIIANP)
GROWTH FACTOR-BETA
SUBSETS IN THE PRESENCE OF CARTILAGE
CHOLESTEROL ACCUMULATION BY LOW DENSITY LIPOPROTEIN RECEPTOR DEFICIENCY OR A CHOLESTEROL-RICH DIET
LOCAL AND SYSTEMIC EFFECTS OF ZOLEDRONATE AND PARATHYROID HORMONE IN EXPERIMENTAL AUTOIMMUNE ARTHRITIS
FRI0048
de Munter Wouter (Netherlands)
Keller Kresten (Denmark)
Im Gun-Il (Korea, Republic Of)
BOUVARD Béatrice (France)
Chair
Abstract
Poster Tour - Poster Area
Poster Tour: Cartilage and joint homeostasy
Chair
Chair
Jacques Peggy (Belgium)
Abstract
Croft Adam (United Kingdom)
Munk Heidi (Denmark)
de Munter Wouter (Netherlands)
Keller Kresten (Denmark)
Im Gun-II (Korea, Republic Of)
Abstract
Abstract
FRI0044
FRI0046
FRI0047
FRI0048
FRI0042
FRI0043
FRI0044
FRI0046
FRI0047
FRI0048
SYNOVIAL FIBROBLASTS FROM PATIENTS WITH RHEUMATOID ARTHRITIS DIFFERENTIATE INTO DISTINCT FIBROBLAST SUBSETS IN THE PRESENCE OF CARTILAGE
HERITABILITY ASSESSMENT OF CARTILAGE COLLAGEN METABOLISM. A TWIN STUDY ON CIRCULATING PRO-COLLAGEN IIA N-TERMINAL PRO-PEPTIDE (PIIANP)
CHOLESTEROL ACCUMULATION BY LOW DENSITY LIPOPROTEIN RECEPTOR DEFICIENCY OR A CHOLESTEROL-RICH DIET ENHANCES OSTEOPHYTE FORMATION DURING EXPERIMENTAL OSTEOARTHRITIS BY ACTIVATING TRANSFORMING GROWTH FACTOR-BETA
LOCAL AND SYSTEMIC EFFECTS OF ZOLEDRONATE AND PARATHYROID HORMONE IN EXPERIMENTAL AUTOIMMUNE ARTHRITIS
OVEREXPRESSION OF PTHRP RELATED MI RNA IN HUMAN BONE MARROW DERIVED STEM CELLS ENHANCES CHONDROGENESIS AND INHIBITS HYPERTROPHY
HYPOXIA IN HUMAN OSTEOARTHRITIC SUBCHONDRAL BONE: A RISK FACTOR FOR LEPTIN PRODUCTION BY OSTEOBLASTS
J OINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY
PREDICTION OF WORSENING OF SKIN FIBROSIS IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS USING THE EULAR SCLERODERMA TRIALS AND RESEARCH (EUSTAR) REGISTRY
EARLY MORTALITY IN SYSTEMIC SCLEROSIS: RATIONALE FOR FORMING A MULTINATIONAL INCEPTION COHORT OF PATIENTS WITH SCLERODERMA (THE INSYNC STUDY)
DECREASED FLOW MEDIATED DILATATION AND NAILFOLD CAPILLAROSCOPIC FINDINGS CAN BE PREDICTORS OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS PATIENTS
TRANSITION FROM PRIMARY TO SECONDARY RAYNAUD’S PHENOMENON: A CAPILLAROSCOPY-BASED PROSPECTIVE STUDY
BENEFICIAL EFFECT OF BUSPIRONE, AN ORALLY AVAILABLE 5-HT1A RECEPTOR AGONIST, ON LOWER ESOPHAGEAL SPHINCTER FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS
CLINICAL FEATURES OF SYSTEMIC SCLEROSIS IN PATIENTS WITH AND WITHOUT RECURRENT DIGITAL ULCERS: FINDINGS FROM THE DUO REGISTRY
HIGH RATE OF FALSE NEGATIVES IN THE EARLY DETECTION OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS BY PULMONARY FUNCTION TESTS
INTERLEUKIN 6 AND VASCULAR DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
SCLEROSIS BY PULMONARY FUNCTION TESTS
MORTALITY IN SYSTEMIC SCLEROSIS PATIENTS

**Poster Tour: Management of SpA 2**

**Chair** van Tubergen Astrid (Netherlands)

**Chair** Poddubnyy Denis (Germany)

**Abstract** van der Heijde Désirée (Netherlands) FRI0419 EFFECT OF CERTOLIZUMAB PEGOL ON INFLAMMATION OF SPINE AND SACROIAC JOINTS IN PATIENTS WITH AXIAL SPONDYLOARTHITIS: 12-WEEK MAGNETIC RESONANCE IMAGING RESULTS OF RAPID-AXSPA STUDY

**Abstract** Baraliakos X (Germany) FRI0420 LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS

**Abstract** Park Won (Korea, Republic Of) FRI0421 A RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 1 STUDY COMPARING THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CT-P13 AND INFliximab IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 54 WEEK RESULTS FROM THE PLANETAS STUDY

**Abstract** Arends Suzanne (Netherlands) FRI0422 SUCCESSFUL DOSE REDUCTION OF TNF-ALPHA BLOCKING AGENTS IN ANKYLOSING SPONDYLITIS PATIENTS WITH STABLE LOW DISEASE ACTIVITY

**Abstract** Song In-Ho (Germany) FRI0425 ROLE OF BASELINE C-REACTIVE PROTEIN IN RESPONSE TO INFliximab PLUS NAPROXEN VS NAPROXEN ALONE IN PATIENTS WITH AXIAL SPONDYLITIS IN THE INFAST STUDY

**Abstract** Van den Bosch Filip (Belgium) FRI0426 SIMILAR LEVELS OF DISEASE ACTIVITY IN PATIENTS WITH OLOQUIARTIC VS. POLYARTICULAR PERIPHERAL SPONDYLOARTHITIS

**Abstract** Kneepkens E (Netherlands) FRI0428 IMMUNOGENICITY, ADALIMUMAB LEVELS AND CLINICAL RESPONSE IN ANKYLOSING SPONDYLITIS PATIENTS DURING 24 WEEKS OF FOLLOW-UP.

**Abstract** Van Sijl Alper (Netherlands) FRI0429 TUMOR NECROSIS FACTOR BLOCKING AGENTS INHIBIT THE PROGRESSION OF PRECLINICAL ATHEROSCLEROSIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS

**Abstract** Çapkin Erhan (Turkey) FRI0424 EFFECTIVE PREVENTION OF NEW INFLAMMATORY BONY LESIONS ON MAGNETIC RESONANCE IMAGING IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHITIS DURING TREATMENT WITH ETANERCEPT OVER 2 YEARS - DATA OF THE ESTHER TRIAL

**Abstract** Myklebust Geirmund (Norway) FRI0427 THE PART OF FUNCTION (HEALTH ASSESSMENT QUESTIONNAIRE) IN THE SF-6D AND EQ-5D UTILITY MEASURES VARIES OVER TIME IN EARLY ARTHRITIS (ESPOIR COHORT): QUESTIONABLE VALIDITY OF DERIVING QUALITY ADJUSTED LIFE YEARS FROM HAQ

**Abstract** Studenic Paul (Austria) FRI0428 VALIDITY OF ANKYLOSING SPONDYLITIS PATIENT-REPORTED OUTCOME INSTRUMENTS IN THE BROAD AXIAL SPONDYLOARTHITIS POPULATION

**Abstract** Verstappen Suzanne (United Kingdom) FRI0429 METHODOLOGICAL CHALLENGES WHEN COMPARING DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF INTERNATIONAL
OBSERVATIONAL STUDIES.

**Poster Tour: Pathogenesis of Lupus and Sjögren's syndrome**

Chair: Mariette Xavier (France)
Chair: Nocturne Gaetane (France)

Abstract: Hillen Maarten (Netherlands) FRIO258 DECREASED TSLP EXPRESSION IN LABIAL SALIVARY GLANDS OF PATIENTS WITH PRIMARY SJÖGRÖN'S SYNDROME IS ASSOCIATED WITH INCREASED T AND B CELL INFLAMMATION AND TISSUE DESTRUCTION

Abstract: Croia Cristina (United Kingdom) FRIO259 ECTOPTIC LYMPHOID STRUCTURES SUPPORT EPSTEIN-BARR VIRUS PERSISTENCE AND AUTOACTIVE PLASMA CELL INFECTION IN SJÖGRÖN'S SYNDROME SALIVARY GLANDS

Abstract: Hoxta Ariela (Italy) FRIO260 DEFINING THE PATHOGENETIC AUTOANTIBODIES IN CONGENITAL HEART BLOCK

Abstract: Greidering Eric (United States) FRIO261 B CELL STIMULATING CYTOKINES BAFF, IL-21 AND IL-33 MRNA EXPRESSION ARE ELEVATED COORDINATELY IN ACTIVE RNP AUTOANTIBODY+ SLE

Abstract: Fejtkova Marketa (Czech Republic) FRIO262 DIFFERENCES IN SERUM MICRONNA PROFILE IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS AND HEALTHY CONTROLS

Abstract: Niewold Timothy (United States) FRIO263 ACTIVATION OF THE INTERFERON PATHWAY IS DEPENDENT UPON AUTOANTIBODIES IN AFRICAN AMERICAN SLE PATIENTS, BUT NOT IN EUROPEAN-AMERICAN SLE PATIENTS

Abstract: McCarthy Eoghan (Ireland) FRIO264 RESTING AND ACTIVATED NK CELL FUNCTION IN SLE PATIENTS.

Abstract: Richez Christophe (France) FRIO265 THE EFFECT OF MYCOPHENOLATE MOFETIL ON DISEASE DEVELOPMENT IN THE GLD.APOE-/- MOUSE MODEL OF ACCELERATEDATHEROSCLEROSIS AND SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract: Sun Lingyun (China) FRIO266 THE MECHANISM OF UMBILICAL CORD MESCCHIVAL STE MCells IN THE UPREGULATION OF REGULATORY T CELLS BY TGF-Μ IN SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract: Jin Ou (China) FRIO267 THE INFLUENCE OF ANTI-MALARIAL DRUGS (HYDROXICHLOROQUINE AND QUINACRINE) ON THE INITIATION OF INTERFERON-7LFA PRODUCTION THROUGH TLR-9 PATHWAY

**Poster Tour: RA - Anti-TNF therapy**

Chair: O'Dell James (United States)
Chair: Binbaum Neal (United States)

Abstract: Kesetouke E (Canada) FRIO161 RESPONSE TO ETANECPT-METHOTREXATE THERAPY AND ETANECPT MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS WITH MODERATE AND SEVERE DISEASE IN THE CAMEO TRIAL

Abstract: Nesibilt Andrew (United Kingdom) FRIO162 INVESTIGATION INTO THE BINDING AFFINITY OF CERTOLIZUMAB PEGOL TO FCRN AND FUNCTIONAL CONSEQUENCES FOR FCRN-MEDIATED TRANSCYTOSIS: COMPARISON TO INFlixIMAB, ADA Limabab and ETANECPT

Abstract: Rotar ?iga (Slovenia) FRIO163 SURVIVAL OF THE SECOND BIOLOGIC AFTER THE FIRST ANTI-TNF FAILURE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: DATA FROM BIORX.SI REGISTRY

Abstract: Yoo Do Hyun (Korea, Republic Of) FRIO164 LOCAL TUBERCULOSIS INCIDENCE AFFECTS THE RATE OF POSITIVE CONVERSION IN THE QUANTIFERON®-TB GOLD TEST AMONG PATIENTS RECEIVING INFILXIMAB OR CT-P13 THERAPY

Abstract: Ducourau Emile (France) FRIO165 A PREDICTION TOOL FOR DRUG MONITORING OF ADALimabUMAB IN RHEUMATOID ARTHRITIS.

Abstract: Baeklundt Eva (Sweden) FRIO166 DOES BIOLOGICAL THERAPY ALTER THE LYMPHOMA RISK OR DISTRIBUTION OF LYMPHOMA SUBTYPES IN PATIENTS WITH RA?

Abstract: Viguier Manuelle (France) FRIO167 ALOPECIA AREATA OCCURRING DURING TNF BLOCKERS THERAPY: A FRENCH MULTICENTRIC SURVEY

Abstract: Plasencia Chahuida (Spain) FRIO168 ETANECPT SERUM TROUGH LEVELS ARE CORRELATED WITH CLINICAL ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS WITH LONG-TERM TREATMENT WITH ETANECPT

Abstract: Low A (United Kingdom) FRIO169 INFLUENCE OF ANTI-TNF THERAPY ON THE RISK OF MYOCARDIAL INFARCTION IN SUBJECTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE BSRBR-RA

Abstract: Herman Ann (United States) FRIO170 PHARMACODYNAMIC BIOMARKERS DEMONSTRATE OVERLAPPING AND DISTINCT BIOLOGICAL PATHWAYS FOR LYMPTOTOXIN-7LPHA AND TUMOR NECROSIS FACTOR-ALPHA IN PATIENTS WITH RHEUMATOID ARTHRITIS

**Poster Tour: RA - prognosis, predictors and outcome**
DISEASE ACTIVITY AT THREE MONTHS IS AN EXCELLENT PREDICTOR OF LONG-TERM TREATMENT FAILURE IN ACTIVELY TREATED RHEUMATOID ARTHRITIS PATIENTS, 5-YEAR RESULTS OF THE NEO-RACO TRIAL.

A STUDY OF INCIDENCE, RISK FACTORS AND ECONOMIC BURDEN OF OSTEOARTICULAR FRACTURE IN RHEUMATOID ARTHRITIS (RA): RESULTS FROM TWO UK INCEPTION COHORTS.

OUTCOMES OF TWO YEARS OF REMISSION STEERED TREATMENT IN EARLY ARTHRITIS PATIENTS.

RHEUMATOID ARTHRITIS PATIENTS HAVE WORSE OUTCOMES AFTER TOTAL HIP REPLACEMENTS COMPARED WITH OSTEARTHROSIS PATIENTS.

HAQ BASELINE VALUES IN AN INTERNATIONAL REGISTRY OF RA PATIENTS DURING THE ERA OF BIOLOGIC THERAPIES: THE 2013 METEOR DATABASE.

HIGH BODY MASS INDEX IS ASSOCIATED WITH A REDUCED RISK OF DEVELOPING RHEUMATOID ARTHRITIS IN MEN.

BIOMARKER-BASED ESTIMATES OF RISK OF RADIOGRAPHIC PROGRESSION IN THE LEIDEN EARLY ARTHRITIS COHORT.

OBESE PATIENTS WITH RHEUMATOID ARTHRITIS HAVE REDUCED RESPONSE RATES TO BIOLOGIC ANTI-RHEUMATIC AGENTS: A COMPARISON BETWEEN EUROPEAN AND AMERICAN RA PATIENTS.

TREAT TO TARGET: DEFINING THE OPTIMUM TARGET TO PREVENT RADIOGRAPHIC EROSION PROGRESSION DURING THE FIRST YEAR OF TREATMENT IN AN EARLY RHEUMATOID ARTHRITIS COHORT.

THE VALUE OF GENE SIGNATURES IN THE DIAGNOSIS OF PRE-CLINICAL RA.

USING ADAPTIVE CHOICE BASED CONJOINT (ACBC) ANALYSIS TO STUDY PATIENTS' PREFERENCES REGARDING PHARMACEUTICAL TREATMENT FOR OSTEOARTHRITIS (OA).

PAIN, PHYSICAL FUNCTION AND LIFE QUALITY EVALUATION IN PATIENTS DIAGNOSED OF KNEE OR HIP OSTEOARTHRITIS.

AUDIT OF UPTAKE IN PRIMARY CARE OF SEASONAL AND PNEUMOCOCCAL VACCINATION BY RHEUMATOLOGY PATIENTS.

USING ADAPTIVE CHOICE BASED CONJOINT (ACBC) ANALYSIS TO STUDY PATIENTS' PREFERENCES REGARDING PHARMACEUTICAL TREATMENT FOR OSTEOARTHRITIS (OA).

AUDIT OF UPTAKE IN PRIMARY CARE OF SEASONAL AND PNEUMOCOCCAL VACCINATION BY RHEUMATOLOGY PATIENTS.

PREVALENCE OF THE TIGHT HAMSTRING SYNDROME (THS) IN A SCHOOL POPULATION.
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Nellore Kavitha (India)</th>
<th>FR0004</th>
<th>DISCOVERY OF POTENT AND SELECTIVE RETINOID RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) INVERSE AGONISTS FOR THE TREATMENT OF TH17 MEDIATED DISEASES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>Gao Wei (Ireland)</td>
<td>FR0005</td>
<td>SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 REGULATES SYNOVIAL INFLAMMATION THROUGH NOTCH/HIF1 PATHWAYS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Maeda Toshihisa (Japan)</td>
<td>FR0006</td>
<td>DECOY RECEPTOR 3 REGULATES THE EXPRESSION OF Tryptophan Hydroxylase TPH1 IN RHEUMATOID SYNOVIAL FIBROBLASTS</td>
</tr>
<tr>
<td>Abstract</td>
<td>Scanu Anna (Italy)</td>
<td>FR0007</td>
<td>HIGH-DENSITY LIPOPROTEINS SUPPRESS THE INFLAMMATORY RESPONSE TO MSU CRYSTALS IN VIVO</td>
</tr>
<tr>
<td>Abstract</td>
<td>Aringer Martin (Germany)</td>
<td>FR0008</td>
<td>EVIDENCE FOR INCREASED ACTIVITY OF INTERLEUKIN-6 (IL-6) IN SEROPOSITIVE RHEUMATOID ARTHRITIS (RA+), AND DIFFERENTIAL TUMOUR NECROSIS FACTOR (TNF) RECEPTOR EXPRESSION BETWEEN RA+ AND SERONEGATIVE RA.</td>
</tr>
<tr>
<td>Abstract</td>
<td>Van Roon Joel A. (Netherlands)</td>
<td>FR0009</td>
<td>IL-4-10 SYNERKINE: A NOVEL ANTI-INFLAMMATORY DRUG TO INHIBIT IMMUNOPATHOLOGY IN RHEUMATIC DISEASES</td>
</tr>
</tbody>
</table>

**Friday 14.06.2013 13:30 - 15:00**

**What is New (WIN) - Hall 6**

**WIN Session 6**

- **Speaker** Gomez-Reino Carnota Juan Jesus (Spain) | SP0114 | Psoriatic arthritis
- **Speaker** Kloppenburg Margreet (Netherlands) | SP0115 | Osteoarthritis

**Clinical Science Session - Hall 8**

**Relapsing and remitting arthritis: when to stop therapy**

- **Chair** Roth Johannes (Germany)
- **Chair** Alvaro-Gracia Jose-Maria (Spain)
- **Speaker** Wulffraat Nico (Netherlands) | SP0115 | Prediction of response to therapy-Lessons from JIA
How to Treat / Manage (HOT) - Hall 7

HOT Session 7

Speaker Gottenberg Jacques-Eric (France) Sjögren’s syndrome
Speaker Vencovsky Jiri (Czech Republic) Myositis

Clinical Science Session - Room N103/104

Osteoporotic fractures and fracture healing in osteoporosis
Chair Lems Willem F. (Netherlands)
Chair Buttgereit Frank (Germany)
Speaker Bianchi Gerolamo (Italy) SP0117 Epidemiologic burden of osteoporotic fractures
Speaker Lems Willem F. (Netherlands) SP0118 Current strategies of primary and secondary fracture prevention
Speaker Duda Georg (Germany) SP0119 Biomechanical and immunological aspects of fracture healing: Update 2013
Abstract Sehgal Amrita (United States) OP0270 OSTEOPOROTIC HIP FRACTURES IN EXTREME ELDERLY MEN: A GROWING PROBLEM

Challenges in Clinical Practice Session - Hall 4

Refractory lung fibrosis in rheumatic diseases
Chair Kowal-Bielecka Otylia (Poland)
Chair Valentini Gabriele (Italy)
Presenter Gladue Heather (United States) Case 2 presentation: Lung transplantation in rheumatic lung fibrosis
Discussant Khanna Dinesh (United States) Case 2 discussion: Lung transplantation - ready for prime time in rheumatic lung fibrosis?
Presenter Lynch Bernadette M. (United Kingdom) SP0120 Case 1 presentation: Scleroderma lung disease
Discussant Denton Christopher (United Kingdom) How to treat interstitial lung disease in rheumatic diseases - lessons beyond cyclophosphamide

Outcomes Science Session - Room N101/102

Referring patients with low back pain and spondyloarthritis
Chair van der Horst-Bruinsma Irene (Netherlands)
Chair Rudwaleit Martin (Germany)
Speaker Marzo-Ortega Helena (United Kingdom) How to develop referral criteria
Speaker van Tubergen Astrid (Netherlands) SP0121 How to implement referral criteria
Abstract van den Berg R. (Netherlands) OP0271 PREVALENCE OF STRUCTURAL LESIONS ON MRI OF THE SACROILIAC JOINTS IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS AND PATIENTS WITH BACK PAIN
Abstract De Hooge Marouk (Netherlands) OP0272 PREVALENCE OF STRUCTURAL LESIONS MRI-SPINE IN PATIENTS WITH (POSSIBLE) AXIAL SPONDYLOARTHRITIS (AXSAP) INCLUDED IN THE SPACE-COHORT
Abstract Weber Ulrich (Switzerland) OP0273 DOES SPINAL MRI ADD INCREMENTAL DIAGNOSTIC VALUE TO MRI OF THE SACROILIAC JOINTS ALONE IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
Clinical Science Session - Room N105/106

Targeting vascular remodelling and PAH in systemic sclerosis

Chair Allanore Yannick (France)
Chair Smith Vanessa (Belgium)
Speaker Seibold James R. (United States) SP0122 Pulmonary arterial hypertension in the connective tissue diseases - the new era of evidence
Speaker Humbert Marc (France) SP0123 Pulmonary vascular remodelling in systemic sclerosis - new targets for therapy on the horizon
Speaker Matucci-Cerinic Marco (Italy) Digital ulcers in connective tissue diseases - a matter of early detection and classification
Abstract Cutolo Maurizio (Italy) OP0275 NAILFOLD VIDEOMICROSCOPY AND OTHER PREDICTIVE FACTORS ASSOCIATED WITH NEW DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: DATA FROM THE CAP STUDY
Abstract Khanna Dinesh (United States) OP0274 RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE-TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION

Pulmonary arterial hypertension in the connective tissue diseases - the new era of evidence

Pulmonary vascular remodelling in systemic sclerosis - new targets for therapy on the horizon

OP0277-PC SP0125 PERSISTENCE WITH ANTIOSTEOPOROTIC DRUGS: A RETROSPECTIVE POPULATION-BASED COHORT STUDY

Hazards in modern treatment of inflammatory arthritis

Modern RA treatment

Advances in the treatment of spondyloarthritis

Basic and Translational Science Session - Room N107/108

New pathways in spondyloarthritis: the IL23 axis and beyond

Chair McGonagle Dennis (United Kingdom)
Chair van Duivenvoorde Leonie (Netherlands)
Speaker Elewaat Dirk (Belgium) SP0126 NKT and related cells: key roles in spondyloarthritis?
Speaker Sherlock Jonathan (United Kingdom) SP0127 IL23: a signal to the enthesis?
Speaker Baeten Dominique (Netherlands) IL23-IL17: translational and clinical insights into spondyloarthritis
Abstract Ciccia Francesco (Italy) OP0278 AUTOPHAGY, BUT NOT THE UNFOLDED PROTEIN RESPONSE, REGULATES THE EXPRESSION OF IL-23 IN THE GUT OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND SUBCLINICAL GUT INFLAMMATION
Abstract Neerinckx Barbara (Belgium) OP0279 THE UNFOLDED PROTEIN RESPONSE GENES IN SYNOVIAL AND BLOOD MONONUCLEAR CELLS OF HLA-B27 POSITIVE ANKYLOSING SPONDYLITIS PATIENTS IS NOT INCREASED COMPARED TO OTHER ARTHRITIS PATIENTS AND HEALTHY CONTROLS.

Basic and Translational Science Session - Room N109/110

Resolving inflammation through endogenous pathways

Chair Gilroy Derek (United Kingdom)
<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Affiliation</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Tas Sander W.</td>
<td>Netherlands</td>
<td>Developing small molecule agonists to resolve inflammation</td>
</tr>
<tr>
<td>Speaker</td>
<td>Leroy Xavier</td>
<td>Switzerland</td>
<td>The melancortin anti-inflammatory paradigm</td>
</tr>
<tr>
<td>Speaker</td>
<td>Perretti Mauro</td>
<td>United Kingdom</td>
<td>Immunoregulatory properties of galectins</td>
</tr>
<tr>
<td>Speaker</td>
<td>Mascalfroni Iván</td>
<td>United States</td>
<td></td>
</tr>
</tbody>
</table>

**Educational Session - Room N111/112**

**Young Investigator Forum 1: Getting your message across**

| Chair          | Bijlsma Johannes W.J.                     | Netherlands                  | Complex basis for divergent arthritis susceptibility in mast cell-deficient mice |
| Chair          | Boupitas Dimitris                         | Greece                       | Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the United States and the influence of TNF inhibitors |
| Chair          | Panayi Gabriel S                          | United Kingdom               | Verbal administration patient global assessments and assessments of disease activity demonstrate good correlation with traditional written versions: The talk-the-line observational study. |
| Abstract       | Nigrovic Peter                            | United States                | Severe extra-articular manifestations in rheumatoid arthritis: risk factors and incidence in relation to treatment with TNF-inhibitors |
| Abstract       | Beukelman Timothy                         | United States                | Transitional and memory B cell analysis is an essential tool to anticipate clinical relapse in rheumatoid arthritis (RA) patients treated with rituximab |
| Abstract       | Caplan Liron                              | United States                | Cellular and humoral responses to varicella-zoster virus in patients with autoimmune diseases |

**Fellows in Training Session - Room N113/114**

**World Rheumatology: education and training offerings for fellows and other health professionals**

| Chair          | Dougados Maxime                           | France                       | APLAR offering                                                        |
| Chair          | Li Zhianguo                               | People's Republic of China   | APLAR offering                                                        |
| Speaker        | Li Zhianguo                               | People's Republic of China   | The APLAR offering                                                    |
| Speaker        | Oyoo Omondi G.                            | Kenya                        | The APLAR offering                                                    |
| Speaker        | Reveille John D.                          | United States                | The PANLAR offering                                                  |
| Speaker        | Ramiro Sofia                              | Portugal                     | The EULAR offering                                                   |

**Practical Skills Session - Room N117**

**Ultrasound Basic 2**

| Chair          | Naredo Esperanza                          | Spain                        | How to distinguish normal from abnormal findings                      |
| Speaker        | Kane David                                | Ireland                      | How does anatomy help to learn ultrasound?                            |
| Speaker        | Möller Ingrid                             | Spain                        | The practical case: is it really easy to distinguish gout from CPPD by ultrasound? Live case with patient |
| Speaker        | Dejaco Christian                          | Austria                      | Hands-on scanning in groups with patients with gout and CPPD          |
| Speaker        | Schmidt Wolfgang A.                       | Germany                      |                                                                        |

**EULAR Projects in Epidemiology and Health Services - Room N118**

**Guidelines for the conduct and report of Trial Extension Studies**
EULAR Projects in Education and Training - Room N115

Educational pearls

Chair: Lundberg Ingrid (Sweden)
Chair: Sivera Francisca (Spain)
Speaker: Lundberg Ingrid (Sweden)
Abstract: Ndosi Mwidimi (United Kingdom)
Abstract: Dougados Maxime (France)
Abstract: Devillers Hervé (France)
Abstract: Piperno Muriel (France)
Abstract: Myasoutova Leysan (Russian Federation)
Abstract: Ciechomska Anna (United Kingdom)
Abstract: sunmboye kehinde (United Kingdom)

VALIDATION OF THE EDUCATIONAL NEEDS ASSESSMENT TOOL AS A GENERIC INSTRUMENT FOR RHEUMATIC DISEASES IN 7 EUROPEAN COUNTRIES
IMPACT OF A NURSE LED PROGRAM OF PATIENT SELF-ASSESSMENT OF DISEASE ACTIVITY ON THE MANAGEMENT OF RHEUMATOID ARTHRITIS: RESULTS OF A PROSPECTIVE, MULTICENTRE, RANDOMIZED, CONTROLLED TRIAL (COMEDRA)
ASSESSMENT OF PATIENT NEEDS TO DESIGN A PATIENT EDUCATION PROGRAM IN SYSTEMIC LUPUS ERYTHEMATOSUS.
EFFECTS OF AN EDUCATIONAL PROGRAM ON THE SAFETY KNOWLEDGE AND SKILLS OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED BY BIOLOGICS
THE EFFECTIVENESS OF EDUCATIONAL PROGRAMS FOR PATIENTS WITH ANKYLOSING SPONDYLITIS IN CLINICAL PRACTICE.
LESSONS LEARNED FROM THE SCOTTISH RHEUMATOLOGY ULTRASOUND MENTORING NETWORK PROJECT.
COMPARATIVE KNOWLEDGE AND PERCEPTION OF TWO CHRONIC DISEASES? RHEUMATOID ARTHRITIS AND DIABETES MELLITUS IN PRIMARY CARE: TESTING WATERS LOCALLY...

Joint Clinical / HPR / PARE Session - Room N116

Family planning, pregnancy and parenthood

Chair: Koksvik Hege Svean (Norway)
Speaker: Khan Homaia Sofia (United Kingdom)
Speaker: Brat Meroç (Spain)
Speaker: Tincani Angela (Italy)
Abstract: Mateus Elsa (Portugal)
Abstract: Sagen Joachim.Sagen (Norway)

By choice - considerations on pregnancy and parenthood when you have RA
Musculoskeletal disorders and how they affect the process of paternity – a psychological perspective
The challenge of supporting a person with RMD to become a parent- a clinical perspective
FAMILY PLANNING AND JIA: INFERTILITY AND PARENTHOOD
EMPOWERMENT SEMINARS FOR YOUNG ADULTS WITH RMDS AUTHOR: JOACHIM SAGEN, EMPLOYEE OF THE NORWEGIAN RHEUMATISM ASSOCIATION

Friday 14.06.2013 15:30 - 17:00

What is New (WIN) - Hall 6

WIN Session 7

Speaker: Müller-Ladner Ulf (Germany)
Speaker: Ralston Stuart H. (United Kingdom)

Systemic sclerosis and myositis
Osteoporosis and Bone diseases
Clinical Science Session - Hall 8

Osteoarthritis: a multiple phenotypes disease

Chair: Berenbaum Francis (France)
Chair: Herrero-Beaumont Gabriel (Spain)

Speaker: Bijlsma Johannes W.J. (Netherlands)
Any use in phenotyping OA patients?

Speaker: Macfarlane Gary J. (United Kingdom)
Low back pain and spine OA, is there a link?

Abstract: Wesseling Janet (Netherlands) OP0292
DIFFERENT PAIN TRAJECTORIES IN EARLY SYMPTOMATIC KNEE OA; 5 YEAR FOLLOW-UP OF CHECK (COHORT HIP & COHORT KNEE) STUDY

Abstract: Stoppeolio Laura (United Kingdom) OP0293
INCREASED NERVE GROWTH FACTOR IN THE SYNOVIAL OF PEOPLE WITH PAINFUL KNEE OSTEARTHRITIS.

Abstract: Todorov Plamen (Bulgaria) OP0294
ULTRASONOGRAPHIC STUDY OF ERECTOR SPINAES CAUDAL ENTHESOPATHY - COULD "NONSPECIFIC" LOW BACK PAIN BECOME MORE SPECIFIC

Abstract: Murphy Susan (Ireland) OP0295
LOW BACK PAIN IN PRIMARY CARE - PRELIMINARY PILOT RESULTS OF GROUP EXERCISE/EDUCATION INTERVENTION USING THE STARTBACK SCREENING TOOL TO SUBGROUP PATIENTS.

How to Treat / Manage (HOT) - Hall 7

HOT Session 8

Speaker: Pitzalis Costantino (United Kingdom)
Treatment of undifferentiated / early arthritis (drug therapy)

Speaker: Porter Duncan (United Kingdom) SP0134
Management of RA from the beginning

Clinical Science Session - Room N103/104

What is coming after TNFi in axial SpA? NSAIDs again or new drugs?

Chair: Landewé Robert B.M. (Netherlands)
Chair: Baraliakos Xenophon (Germany)

Speaker: Haroon Nigel (Canada)
NSAIDs in axial SpA: new perspectives of an old drug

Speaker: Lie Elisabeth (Norway) SP0135
Switching TNF-blockers: what is the evidence?

Speaker: Sieper Joachim (Germany)
Non-TNFi biologicals: new kids on the block?

Challenges in Clinical Practice Session - Hall 4

Opportunistic infections in rheumatic diseases

Chair: Schett Georg (Germany)
Chair: Manger Bernhard (Germany)

Presenter: Saraiva da Silva Junior Francisco (Brazil)
Case 1 presentation: Active lupus or confounding infection?

Discussant: Castro Da Rocha Ailton (Brazil)
Case 1 discussion: Active lupus or confounding infection?

Presenter: Hueber Axel (Germany)
Case 2 presentation: Increasing liver enzymes in a patient on RA-therapy

Discussant: Manger Bernhard (Germany)
Case 2 discussion: Increasing liver enzymes in a patient on RA-therapy

Outcomes Science Session - Room N101/102

Administrative databases: How safe is it to use them as a research source?

Chair: Michaud Kaleb (United States)
<table>
<thead>
<tr>
<th>Chair</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic and Translational Science Session - Room N109/110</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Basic and Translational Science Session - Room N107/108</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary Care Session - Room Retiro</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PreS Session - Room N105/106</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Cholesterol in the middle

Chair: Gonzalez-Gay Miguel Angel (Spain)
Chair: Tincani Angela (Italy)
Speaker: Straub Rainer H. (Germany)
Speaker: Perretti Mauro (United Kingdom)
Speaker: McMahon Maureen (United States)
Abstract: Rosenblatt L (United States)
Abstract: Broder Anna (United States)

Speaker: Kviatkovsky Milla (United States)
Speaker: Tauber Marie (France)
Abstract: Davis Holly (United Kingdom)
Abstract: Aziz Nader (United Kingdom)

Educational Session - Room N111/112

Young Investigator Forum 2: Getting your message across

Chair: Boumpas Dimitris (Greece)
Chair: Aleataha Daniel (Austria)
Abstract: Gron Kathrine (Denmark)
Abstract: Kviatkovsky Mila (United States)
Abstract: Tauber Marie (France)
Abstract: Davis Holly (United Kingdom)
Abstract: Aziz Nader (United Kingdom)

Health Professionals Workshop Session - Room N113/114

Using psychological approaches in the clinical setting: What can we do and how?

Chair: Bode Christina (Netherlands)
Chair: Taylor Julie (United Kingdom)
Speaker: Dures Emma (United Kingdom)
Speaker: Hewlett Sarah (United Kingdom)
Speaker: Zangi Heidi A. (Norway)
Speaker: Arends Roos (Netherlands)

Practical Skills Session - Room N117

MRI Advanced 1

Chair: Ostergaard Mikkel (Denmark)
Chair: Hermann Kay-Geert (Germany)
Speaker: Diekhoff Torsten (Germany)
Speaker: Lambert Robert (Canada)
Speaker: Peterfy Charles (United States)
Speaker: Lambert Robert (Canada)
Practical Skills Session - Room N118

Diagnostic and prognostic use of capillaroscopy in rheumatology 2

Chair Cutolo Maurizio (Italy)
Chair Herrick Ariane L. (United Kingdom)
Chair Smith Vanessa (Belgium)
Speaker Herrick Ariane L. (United Kingdom) SP0042 Raynaud's phenomenon: a clinical symptom that must be diagnosed by capillaroscopy
Speaker Hermann Walter (Germany) Selecting the most appropriate capillaroscopic device: pros and cons
Speaker Smith Vanessa (Belgium) SP0043 How to score the qualitative capillaroscopic patterns
Speaker Sulli Alberto (Italy) SP0153 How to distinguish normal from pathological capillaroscopic patterns
Speaker Cutolo Maurizio (Italy) SP0154 The prognostic value of the capillaroscopic analysis
Speaker Smith Vanessa (Belgium) Practical session with videocapillaroscopy in living patients and general discussion

PARE Session - Room N116

What is new? Latest advances in management and treatment

Chair Bosworth Alisa (United Kingdom)
Chair Mandl Peter (Austria)
Speaker Conaghan Philip (United Kingdom) SP0155 Latest advances in managing degenerative conditions
Speaker Gossec Laure (France) SP0156 Latest advances in biological treatment – safety and efficacy
Speaker Moderators (-) Moderated discussion with and feedback from the audience

Saturday 15.06.2013 08:30 - 10:00

WIN Session 8

Speaker Symmons Deborah (United Kingdom) SP0157 Infections and rheumatic diseases
Speaker Zink Angela (Germany) SP0158 Comorbidity in rheumatic diseases

Clinical Science Session - Hall 8

What we learn from osteoarthritis cohorts?

Chair Nevitt Michael (United States)
Chair Monfort Jordi (Spain)
Speaker Nevitt Michael (United States) SP0159 The osteoarthritis initiative
Speaker van Spli Erwin (W.E.) (Netherlands) SP0159 The CHECK cohort
Speaker Peat George M. (United Kingdom) SP0160 CAS: a primary care cohort
Speaker Guillemin Francis (France) SP0161 The KHOALA cohort

How to Treat / Manage (HOT) - Hall 7

HOT Session 9
Clinical Science Session - Room N103/104

Clinical trials addressing macrophage and chemokines in RA

Chair Magalhães Laurindo Leda Maria (Brazil)
Chair Cantagrel Alain (France)
Speaker Hamilton John (Australia) SP0162 The monocyte-macrophage system and the influence of cytokines/CSFs
Speaker Burmester Gerd Rüdiger (Germany) The clinical data of GM-CSF inhibition in RA
Speaker Tak Paul-Peter (Netherlands) Chemokine blockade in rheumatoid arthritis
Abstract Bombardieri Michele (United Kingdom) OP0303 MAVRILUMAB REDUCES PRO-INFLAMMATORY CYTOKINES AND CD68 POSITIVE MACROPHAGES IN SYNOVIAL EXPLANTS FROM RHEUMATOID ARTHRITIS SUBJECTS ENGRAFTED INTO SCID/BEIGE MICE.
Abstract Hartkamp Linda (Netherlands) OP0304 BTK INHIBITION SUPPRESSES INFLAMMATORY CYTOKINE PRODUCTION AND AFFECTS GENE EXPRESSION IN HUMAN MACROPHAGES AND RA SYNOVIAL TISSUE EXPLANTS

Challenges in Clinical Practice Session - Hall 4

Osteoporotic fractures despite maximum treatment

Chair Lems Willem F. (Netherlands)
Chair Bianchi Gerolamo (Italy)
Presenter Bock Oliver (Germany) Case 1 presentation: Anti-osteoporotic drugs do not always work: examples of failure
Discussant Felsenberg Dieter (Germany) Case 1 discussion: How to switch anti-osteoporotic drugs in case of ineffectiveness?
Presenter Caimmi Cristian (Italy) Case 2 presentation: Vertebroplasty and kyphoplasty
Discussant Adami Silvano (Italy) Case 2 discussion: Vertebroplasty and kyphoplasty: advantages and disadvantages

Outcomes Science Session - Room N101/102

Challenges in outcome measures

Chair Castellar Geraldo (Brazil)
Chair Distler Oliver (Switzerland)
Speaker Distler Oliver (Switzerland) Using outcome measures in orphan diseases
Abstract Santiago Tânia (Portugal) OP0305 ASSESSMENT OF SKIN INVOLVEMENT BY ACOUSTIC RADIATION FORCE IMPULSE (ARFI) IMAGING IN PATIENTS WITH SYSTEMIC SCLEROSIS
Abstract Pazzola Giulia (Italy) OP0306 EVALUATION OF DISEASE ACTIVITY USING FDG PET-CT IN PATIENTS WITH LARGE VESSEL VASCULITIS
Speaker Landewé Robert B.M. (Netherlands) When outcome measures fool us
Speaker Ruperto Nicola (Italy) SP0163 Switching measures on the transition to adulthood

Basic and Translational Science Session - Room N105/106

EFIS - EULAR Session: Tertiary Lymphoid Structures in diseases: good or bad for the patients?

Chair Sautes-Fridman Catherine (France)
Chair Schett Georg (Germany)
<table>
<thead>
<tr>
<th>Speaker</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dieu-Nosjean Marie-Caroline (France)</td>
<td>Good prognostic value of TLS in lung cancer</td>
<td></td>
</tr>
<tr>
<td>Randall Troy (United States)</td>
<td>TLS in infectious diseases</td>
<td></td>
</tr>
<tr>
<td>Verweij Cornelis (Netherlands)</td>
<td>TLS in autoimmunity</td>
<td></td>
</tr>
<tr>
<td>Olivier Brenda J. (Netherlands)</td>
<td>Neuronal control of TLS in the intestine</td>
<td></td>
</tr>
</tbody>
</table>

**Basic and Translational Science Session - Room N107/108**

**Enter the regenerative rheumatologist - endogenous stem cells and joint repair in osteoarthritis**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>McGonagle Dennis (United Kingdom)</td>
<td></td>
<td>Joint distraction and cartilage regeneration - what is the basis for structural repair?</td>
</tr>
<tr>
<td>Vincent Tonia (United Kingdom)</td>
<td></td>
<td>Bone marrow and synovial fluid stem cells in vivo as drivers of spontaneous tissue repair</td>
</tr>
<tr>
<td>Mastbergen Simon (Netherlands)</td>
<td></td>
<td>The synovium as a stem cell niche for joint repair</td>
</tr>
<tr>
<td>Jones Elena (United Kingdom)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>de Bari Cosimo (United Kingdom)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kendo Masahiro (Japan)</td>
<td></td>
<td>INHIBITORY EFFECTS OF IL-17 ON CHONDROGENIC DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELLS THROUGH THE PHOSPHORYLATION OF SOX9</td>
</tr>
</tbody>
</table>

**Basic and Translational Science Session - Room N109/110**

**The science of pain**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maclarenne Gary J. (United Kingdom)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee Yvonne (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee Yvonne (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McMahon Stephen (United Kingdom)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dickenson Anthony (United Kingdom)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kuttapitiya Anasuya (United Kingdom)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fellows in Training Session - Room N111/112**

**How to optimize health professional input in your practice**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Tubergen Astrid (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cornell Patricia (United Kingdom)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ammerlaan Judy (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masselink Ilse S. (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hagen Kåre Birger (Norway)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cornell Patricia (United Kingdom)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chair</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Health Professionals Session - Room N113/114**

**Optimization of care for patients with hip and knee osteoarthritis**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dekker Joost (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>de la Torre-Afek Jenny (Spain)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smirk Agnes (Netherlands)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chair</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Beating osteoarthritis (BART): the evaluation of a stepped care strategy**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Title/Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sp0164: Good prognostic value of TLS in lung cancer
Sp0165: Neuronal control of TLS in the intestine
Sp0166: Joint distraction and cartilage regeneration - what is the basis for structural repair?
Sp0167: Bone marrow and synovial fluid stem cells in vivo as drivers of spontaneous tissue repair
Sp0168: The synovium as a stem cell niche for joint repair
OP0307: Inhibitory effects of IL-17 on chondrogenic differentiation of human mesenchymal stem cells through the phosphorylation of SOX9
OP0308: Identifying target molecules mediating pain processing in osteoarthritis: Assessing TRPV1, TRPA1 and TRPM8 expression in joint tissue

31.05.2013
<table>
<thead>
<tr>
<th>Speaker</th>
<th>Management of primary care for people with knee osteoarthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>van der Esch Martin (Netherlands)</td>
<td>Management of secondary care as support for primary care for people with hip or knee osteoarthritis: the AMS-OA cohort study</td>
</tr>
<tr>
<td>Thorstensson Carina (Sweden)</td>
<td>Implementation of OA care pathways in Sweden: Better management of Osteoarthritis (BOA)</td>
</tr>
<tr>
<td>Knoop Jesper (Netherlands)</td>
<td>KNEE JOINT STABILIZATION THERAPY IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: A RANDOMIZED, CONTROLLED TRIAL</td>
</tr>
</tbody>
</table>

**Practical Skills Session - Room N117**

**Ultrasound Advanced 2**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Schmidt Wolfgang A. (Germany)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Uson Jacqueline (Spain)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Gargani Luna (Italy)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Bianchi Stefano (Switzerland)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Schmidt Wolfgang A. (Germany)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Naredo Esperanza (Spain)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ultrasound in lung fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultrasound in trauma - what the rheumatologist needs to know</td>
</tr>
<tr>
<td>The practical case: pitfalls for ultrasound in vasculitis - live case with patient</td>
</tr>
<tr>
<td>Hands-on scanning in groups with patients with traumatic lesions OR Quiz</td>
</tr>
</tbody>
</table>

**Joint Clinical / HPR / PARE Session - Room N116**

**Social media in RMD**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Ndosi Mwidi-M (United Kingdom)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Zabalan Codruta (Romania)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Halland Sessilie (Norway)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Gómez-Centeno Antonio (Spain)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Michaud Kaleb (United States)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Meesters Jorit (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Carlsson Anne (Sweden)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient empowerment by social media</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apps that may help clinical practice in rheumatology</td>
</tr>
<tr>
<td>Research in social networks</td>
</tr>
<tr>
<td>Challenges in mapping resources for RMD</td>
</tr>
<tr>
<td>FROM ONE WAY COMMUNICATION TO DIALOGUE, FACEBOOK AND TWITTER</td>
</tr>
</tbody>
</table>

**Saturday 15.06.2013 10:30 - 11:45**

**Poster Tour - Poster Area**

**Poster Tour HP: Getting a grip of the evidence**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Opava Christina H. (Sweden)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>Heine Peter (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Cuperus N. (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Østerås Nina (Norway)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Ahlstrand Inger (Sweden)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Van Den Ende Cornelis (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Lindqvist Elisabet (Sweden)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Björk Mathilda (Sweden)</td>
</tr>
</tbody>
</table>

| GROUP EXERCISE FOR OLDER ADULTS WITH OSTEOARTHRITIS |
| PATIENTS’ PERCEPTIONS OF A SELF-MANAGEMENT BOOKLET FOR HIP OR KNEE OSTEOARTHRITIS: A QUALITATIVE INTERVIEW STUDY |
| LOWER SELF-REPORTED QUALITY OF CARE FOR PERSONS WITH HAND OSTEOARTHRITIS COMPARED TO LOWER LIMB OSTEOARTHRITIS. |
| LOW LEVELS OF PAIN IMPACT ON VALUED LIFE ACTIVITIES IN WOMEN AND MEN WITH RHEUMATOID ARTHRITIS |
| THUMB BASE INVOLVEMENT IN ESTABLISHED HAND OSTEOARTHRITIS |
| COURSE AND OUTCOME OF REHABILITATION CARE IN DIFFERENT RHEUMATOLOGICAL DIAGNOSIS GROUPS. A DESCRIPTIVE STUDY USING THE STAR-ETIC REGISTRY. |
| VALUED LIFE ACTIVITIES: SWEDISH VERSION (VLA-SWE) WITH CULTURAL ADAPTATION, ICF LINKAGE AND PSYCHOMETRIC
<table>
<thead>
<tr>
<th>Poster Tour: A tour around imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong> d’Agostino Maria-Antonietta (France)</td>
</tr>
<tr>
<td><strong>Chair</strong> Poggenborg Rene (Denmark)</td>
</tr>
<tr>
<td><strong>Abstract</strong> Baker J (United States)</td>
</tr>
<tr>
<td><strong>Satellite</strong> SAT0486</td>
</tr>
<tr>
<td><strong>Title</strong> EARLY MRI MEASURES INDEPENDENTLY PREDICT 1- AND 2-YEAR X-RAY PROGRESSION: RESULTS FROM A LARGE CLINICAL TRIAL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Tour: Clinical aspects in paediatric rheumatology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong> Martini Alberto (Italy)</td>
</tr>
<tr>
<td><strong>Chair</strong> Vastert Sebastian (Netherlands)</td>
</tr>
<tr>
<td><strong>Abstract</strong> Kingsbury Daniel (United States)</td>
</tr>
<tr>
<td><strong>Satellite</strong> SAT0436</td>
</tr>
<tr>
<td><strong>Title</strong> SAFETY AND EFFECTIVENESS OF ADAлимУМ in CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS AGED 2 TO &lt;4 YEARS OR &gt;4 YEARS WEIGHING &lt;15 KG</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Tour: Clinical Myositis, overlaps and scleroderma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong> Distler Oliver (Switzerland)</td>
</tr>
<tr>
<td><strong>Abstract</strong> Leite Catarina (Portugal)</td>
</tr>
<tr>
<td><strong>Satellite</strong> SAT0599-HPR</td>
</tr>
<tr>
<td><strong>Title</strong> IMPACT OF PHYSICAL AND PSYCHOLOGICAL SYMPTOMS OF SCLERODERMA</td>
</tr>
<tr>
<td>Chair</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0185</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0186</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0187</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0188</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0189</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0190</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0191</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0192</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0193</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td>SAT0194</td>
</tr>
</tbody>
</table>

**Poster Tour: Gout and crystal arthritis**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Lories Rik (Belgium)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
<td>de Langhe Ellen (Belgium)</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Carter John (United States)</td>
</tr>
<tr>
<td>SAT0352</td>
<td>AN ASSESSMENT OF CHRONIC SYNOVAI-BASED INFLAMMATION AND ITS ROLE WITH SERUM URATE LEVELS.</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Schlesinger Naomi (United States)</td>
</tr>
<tr>
<td>SAT0353</td>
<td>ASSOCIATION OF GOUTY ARTHRITIS SEVERITY WITH PATIENTS? MENTAL AND PHYSICAL HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY AND MEDICAL RESOURCE UTILIZATION.</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Kudaeva Fatima (Russian Federation)</td>
</tr>
<tr>
<td>SAT0354</td>
<td>USEFULNESS OF IMAGING TECHNIQUES IN MIXED CRYSTAL DEPOSITION (PILOT STUDY),</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Malamet Ray (United States)</td>
</tr>
<tr>
<td>SAT0355</td>
<td>REAL WORLD RISK OF INFUSION REACTIONS WITH PEGLOTICASE TREATMENT: FINDINGS FROM POST-APPROVAL US SAFETY DATA</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Horiba Naoshi (Japan)</td>
</tr>
<tr>
<td>SAT0356</td>
<td>THE THERAPEUTIC EFFICACY OF THE NOVEL URICOSURIC AGENT UR-1102 FOR HYPERURICEMIA AND GOUT</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Tausche Anne-Kathrin (Germany)</td>
</tr>
<tr>
<td>SAT0357</td>
<td>AS COMPARED WITH ALLOPURINOL ONLY FEBUXOSTAT PRESERVES VASCULAR FUNCTION IN PATIENTS WITH CHRONIC TOPHACEOUS GOUT</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Sieglova Olga (Czech Republic)</td>
</tr>
<tr>
<td>SAT0358</td>
<td>JOINT MANIFESTATION AND BONE CHANGES IN PATIENTS WITH WILSONE DISEASE</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Perez-Ruiz Fernando (Spain)</td>
</tr>
<tr>
<td>SAT0359</td>
<td>THE NUMBER OF EPISODES OF ACUTE INFLAMMATION ARE ASSOCIATED TO BOTH ACUTE GASTROINTESTINAL AND RENAL COMPLICATIONS ATTRIBUTED TO NSAIDS IN PATIENTS WITH GOUT</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Funck-Brentano Thomas (France)</td>
</tr>
<tr>
<td>SAT0360</td>
<td>HFE C282Y/H63D COMPOUND HETEROZYGOTES ARE AT LOWER RISK OF HEMOCROMATOSIS-RELATED ARTHROPATHY</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Meek Inger (Netherlands)</td>
</tr>
<tr>
<td>SAT0361</td>
<td>HYPERURICEMIA: CAUSE OR CONSEQUENCE OF INCREASED CARDIOVASCULAR RISK</td>
</tr>
</tbody>
</table>

**Poster Tour: Osteoarthritis**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Lafeber Floris (Netherlands)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
<td>Kennedy Norelee (Ireland)</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Reginster JY (Belgium)</td>
</tr>
<tr>
<td>SAT0309</td>
<td>STRONTIUM RANELATE PREVENTS RADIOLOGICAL PROGRESSION IN PATIENTS WITH PRIMARY KNEE OSTEARTHRITIS</td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>Wiuka Anita (Australia)</td>
</tr>
<tr>
<td>SAT0310</td>
<td>USE OF LOW DOSE ASPIRIN IS ASSOCIATED WITH REDUCED MEDIAL TibIAL CARTILAGE LOSS IN SYMPTOMATIC OSTEARTHRITIS: DATA FROM A COHORT STUDY</td>
</tr>
<tr>
<td>Abstract</td>
<td>Petrella Robert (Canada)</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Abstract</td>
<td>Spolidoro Natalia (Brazil)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Østerås Nina (Norway)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Abou-Raya Suzan (Egypt)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Cozdan Co?kun Nilhan (Turkey)</td>
</tr>
<tr>
<td><strong>Poster Tour: Pharmacologic and non-pharmacologic treatment of fibromyalgia and musculoskeletal pain</strong></td>
<td></td>
</tr>
<tr>
<td>Chair</td>
<td>Macfarlane Gary J. (United Kingdom)</td>
</tr>
<tr>
<td>Chair</td>
<td>Atzeni Fabiola (Italy)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Abou-Raya Anna (Egypt)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Deodhar Alul (United States)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Oliveira Hilda (Brazil)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Rodrigues Luiz Claudio (Brazil)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Gamba Maria (Argentina)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Abou-Rayana Anna (Egypt)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Genevay Stephane (Switzerland)</td>
</tr>
<tr>
<td><strong>Poster Tour: Psoriatic arthritis</strong></td>
<td></td>
</tr>
<tr>
<td>Chair</td>
<td>Mandl Peter (Austria)</td>
</tr>
<tr>
<td>Chair</td>
<td>Gossec Laure (France)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Gladman Dafna (Canada)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Lie Elisabeth (Norway)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Haque Naba (Belgium)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Mease P (United States)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Rahman P (Canada)</td>
</tr>
<tr>
<td>Abstract</td>
<td>Coates Laura (United Kingdom)</td>
</tr>
</tbody>
</table>
| Abstract | Eder Lihi (Canada) | SAT0266 | OBESITY IS ASSOCIATED WITH LOWER PROBABILITY OF ACHIEVING SUSTAINED MINIMAL DISEASE ACTIVITY STATE AMONG
PATIENTS WITH PSORIATIC ARTHRITIS

Abstract McInnes I (United Kingdom) SAT0267 SAFETY OF USTEKINUMAB FROM THE PLACEBO-CONTROLLED PERIODS OF PSORIATIC ARTHRITIS AND PSORIASIS CLINICAL DEVELOPMENTAL PROGRAMS

Abstract Huynh Doquyen (United States) SAT0268 ANTI CITRULLINATED PEPTIDE ANTIBODY (ACPA) IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA): CLINICAL RELEVANCE

Abstract Szentpetery Agnes (Ireland) SAT0269 PERIARTICULAR BONE GAIN IN EARLY PSORIATIC ARTHRITIS BUT NOT IN RHEUMATOID ARTHRITIS FOLLOWING ANTI-RHEUMATIC TREATMENT ASSESSED BY DIGITAL X-RAY RADIOGRAPHY

**Poster Tour: RA - Clinical aspects and co-morbidity**

Chair Symmons Deborah (United Kingdom)
Chair Chatzidionysiou Katerina (Sweden)
Abstract Dessein Patrick (South Africa) SAT0043 POTENTIAL DETERMINANTS OFATHEROGENESIS IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM TWO POPULATION GROUPS
Abstract Combe Bernard (France) SAT0044 FIVE-YEAR FAVOURABLE OUTCOME OF PATIENTS WITH EARLY RHEUMATOID ARTHRITIS IN THE 2000S: DATA FROM THE ESPOIR COHORT
Abstract Machaly Sherene (Egypt) SAT0045 SERUM VEGF LEVEL AND ANG2/ANG1 RATIO MEASURED AT BASELINE ARE CORRELATED WITH THE SYNOVIAL BLOOD FLOW MEASURED ONE MONTH LATER IN RHEUMATOID ARTHRITIS
Abstract Ward Lorna (United Kingdom) SAT0046 SHOULD THERE BE DIFFERENT DISEASE ACTIVITY CRITERIA FOR ASSESSMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO ETHNIC BACKGROUNDS?
Abstract C Kapetanovic Meliha (Sweden) SAT0047 IMPACT OF ANTI-RHEUMATIC TREATMENT ON IMMUNOGENICITY OF PANDEMIC H1N1 INFLUENZA VACCINE IN PATIENTS WITH ARTHRITIS
Abstract Mansouri Samia (Morocco) SAT0048 PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH RHEUMATOID ARTHRITIS IN MOROCCO: A CROSS-SECTIONAL STUDY OF 179 CASES.
Abstract Ling Stephanie (United Kingdom) SAT0049 OBESITY IS ASSOCIATED WITH REDUCED IMPROVEMENT IN FUNCTIONAL DISABILITY AFTER 1 YEAR OF TREATMENT: RESULTS FROM AN INCEPTION EARLY RHEUMATOID ARTHRITIS COHORT
Abstract Abou-Raya Anna (Egypt) SAT0050 VOICE IMPAIRMENT IN RHEUMATOID ARTHRITIS PATIENTS: A DISEASE ACTIVITY MARKER OFTEN OVERLOOKED
Abstract Oma Ingvid (Norway) SAT0051 VITAMIN D LEVELS AND INFLAMMATION IN THE AORTIC WALL OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE AND CORONARY ARTERY DISEASE
Abstract Landewé Robert (Netherlands) SAT0052 STRUCTURAL DAMAGE BY RADIOGRAPHY PREDICTS CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS

**Poster Tour: Spondylarthropathies - clinical aspects, biomarkers and imaging**

Chair Ostergaard Mikkel (Denmark)
Chair Juul Pedersen Susanne (Denmark)
Abstract Zufferey Pascal (Switzerland) SAT0224 ANTI-TNF DRUG SURVIVAL IN AXIAL SPONDYLARTHRITIS IS NOT RELATED TO THE NEW ASAS CLASSIFICATION CRITERIA
Abstract De Hooge Manouk (Netherlands) SAT0225 DO BONE MARROW EDEMA (BME) LESIONS IN THE SACROIILIAC JOINT (SIJ) CHANGE INTO FATTY LESIONS OVER A 3-MONTH PERIOD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS (AXSPA)?
Abstract Elewaut Dirk (Belgium) SAT0226 GUT INFLAMMATION IS LINKED TO DEGREE OF BONE MARROW EDEMA IN SACROIILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Abstract Weber Ulrich (Switzerland) SAT0227 LOW DIAGNOSTIC UTILITY OF CANDIDATE DEFINITIONS FOR A POSITIVE MRI OF THE SPINE IN AXIAL SPONDYLOARTHITIS
Abstract van den Berg R. (Netherlands) SAT0228 PERFORMANCE OF MRI COMPARED TO CONVENTIONAL RADIOGRAPHS IN THE DETECTION OF STRUCTURAL LESIONS IN THE SACROIILIAC JOINTS IN PATIENTS WITH RECENT ONSET AXIAL SPONDYLOARTHRITIS
Abstract Moltó Anna (France) SAT0229 SPINE AND SACROILIAC IMAGING ABNORMALITIES SUGGESTIVE OF SPONDYLOARTHRITIS IN EARLY SPONDYLOARTHRITIS. DATA FROM THE DESIR COHORT.
Abstract Kviatkovsky Milla (United States) SAT0230 THE MINIMUM CLINICALLY IMPORTANT IMPROVEMENT AND PATIENT ACCEPTABLE SYMPTOM STATE IN BASDAI AND BASFI IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Abstract Turina Maureen (Netherlands) SAT0231 BASELINE ELEVATED SERUM LEVELS OF CALPROTECTIN AS INDEPENDENT MARKER FOR RADIOGRAPHIC SPINAL
PROGRESSION IN ANKYLOSING SPONDYLITIS

Abstract

Solmaz Dilek (Turkey)

SAT0233

ESTIMATION OF THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) THRESHOLD VALUE WHICH CORRESPONDS TO THE BASDAI ELIGIBILITY CRITERION FOR INITIATION OF ANTI-TNF THERAPY.

Poster Tour: Update on non-TNF inhibitors in RA

Chair
Emery Paul (United Kingdom)

Chair
Goeb Vincent (France)

Abstract
Takeuchi Tsutomu (Japan)

SAT0100

ABATACEPT BIOLOGIC-FREE REMISSION STUDY IN ESTABLISHED RHEUMATOID ARTHRITIS PATIENTS ORION STUDY.

Abstract
Matsutani Takaji (Japan)

SAT0101

ABATACEPT TREATMENT SUPPRESSES T CELL ACTIVATION IN ANTI-CYCIC CITRULLINATED PEPTIDE ANTIBODY (ACPA) POSITIVE RA PATIENTS BUT NOT IN ACPA NEGATIVE RA PATIENTS.

Abstract
Mélet Julien (France)

SAT0102

RITUXIMAB-INDUCED T-CELL DEPLETION IN PATIENTS WITH RHEUMATOID ARTHRITIS: ASSOCIATION WITH CLINICAL RESPONSE.

Abstract
Nüslein H (Germany)

SAT0103

LITHE: TOCILIZUMAB (TCZ) INHIBITS RADIOGRAPHIC PROGRESSION AND IMPROVES PHYSICAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AT 5 YEARS WITH MAINTENANCE OF CLINICAL EFFICACY OVER TIME.

Abstract
Smolen J (Austria)

SAT0104

COMPARISON OF DRUG DISCONTINUATION TO INEFFICACY AND ADVERSE EVENTS BETWEEN ANTI-TNF AGENTS AND NON-ANTI-TNF BIOLOGIC AGENTS? IN ANTI-TNF INADEQUATE RESPONDER RHEUMATOID ARTHRITIS PATIENTS.

Abstract
Burmester Gerd (Germany)

SAT0105

SUMMCTA: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY OF THE SAFETY AND EFFICACY OF TOCILIZUMAB SC VERSUS TOCILIZUMAB IV, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH MODERATE TO SEVERE RA.

Abstract
Galeazzi Mauro (Italy)

SAT0106

PREDICTORS OF RETENTION WITH ABATACEPT IN PATIENTS WHO HAVE FAILED ONE OR MORE BIOLOGIC AGENTS: RESULTS FROM THE INTERNATIONAL, REAL-WORLD ACTION STUDY.

Abstract
Genovese Mark (United States)

SAT0107

EFFICACY AND SAFETY AFTER 64 WEEKS OF IXEKIZUMAB TREATMENT IN A PHASE 2 OPEN LABEL EXTENSION STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS.

Abstract
Galeazzi Mauro (Italy)

SAT0108

DEKAVIL (F8-IL10): A NOVEL ANTI-INFLAMMATORY IMMUNOCYTOKINE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN EARLY DISEASE STAGE: A DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2b STUDY.

Abstract
Smolen J (Austria)

SAT0109

RELATIONSHIP BETWEEN EARLY DISEASE ACTIVITY STATUS AND STRUCTURAL AND FUNCTIONAL CHANGES IN MTX-NAIVE PATIENTS WITH EARLY RA TREATED WITH ABATACEPT PLUS MTX VERSUS MTX ALONE IN THE AGREE TRIAL.

Abstract
Kennedy William (United States)

SAT0110

EFFICACY AND SAFETY OF PATECLIZUMAB (ANTI-LYMPHOTOXIN-ALPHA) IN DMARD-IR PATIENTS: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HEAD-TO-HEAD PHASE 2 STUDY WITH ADALIMUMAB.

Abstract
Saraux Alain (France)

SAT0111

DESCRIPTION OF GLUCOCORTICOID SPARING EFFECT IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED BY TOCILIZUMAB (TCZ) IN REAL LIFE: AN INTERIM ANALYSIS OF THE SPARE-1 STUDY.

Abstract
Senolt Ladislav (Czech Republic)

SAT0112

IMPROVEMENTS IN PATIENT-REPORTED PHYSICAL FUNCTION, PAIN AND GLOBAL DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER TREATMENT WITH NNC0109-0012 (ANTI-IL-20 MAB) IN A PHASE 2A TRIAL.
**How to Treat / Manage (HOT) - Hall 7**

**HOT Session 10 - Update of EULAR Rheumatoid Arthritis Management recommendations**

- **Chair**: Dougdos Maxime (France)
- **Chair**: Kouloumas Marios (Cyprus)
- **Speaker**: Landewé Robert B.M. (Netherlands) - EULAR RA Management Recommendations 2010: How have they performed?
- **Speaker**: Gaujoux Viala Cécile (France) - Systematic Literature Review: Conventional DMARDs
- **Speaker**: Nam Jackie (United Kingdom) - Systematic Literature review: Biological DMARDs
- **Speaker**: Ramiro Sofia (Portugal) - Systematic Literature Review: Safety Aspects
- **Speaker**: Smolen Josef S. (Austria) - EULAR RA Management Recommendations 2013: What is New?

**Clinical Science Session - Room N103/104**

**Clinical trial methodology**

- **Chair**: Porter Duncan (United Kingdom)
- **Chair**: Saag Kenneth (United States)
- **Speaker**: Ravaud Philippe (France) - Observational versus randomised controlled trials
- **Speaker**: Curtis Jeffrey (United States) - New methodology
- **Speaker**: Boutron Isabelle (France) - Non pharmacological clinical trials
- **Speaker**: Ruperto Nicola (Italy) - How to deal with methodology in orphan diseases

**Challenges in Clinical Practice Session - Hall 4**

**Neuropsychiatric complications in SLE**

- **Presenter**: Khamashia Munther (United Kingdom)
- **Chair**: Levy Roger A. (Brazil)
- **Presenter**: Biesen Robert (Germany) - Case 1 presentation: Anticoagulation or immunosuppression?
- **Discussant**: Dönser Thomas (Germany) - Case 1 discussion: Anticoagulation or immunosuppression?
- **Presenter**: Bertias Georges (Greece) - Case 2 presentation: Demyelination in SLE
- **Discussant**: Boumpas Dimitris (Greece) - Case 2 discussion: Demyelination in SLE: diagnostic and therapeutic challenges

**Outcomes Science Session - Room N101/102**

**How to assess comorbidities**
### Basic and Translational Science Session - Room N107/108

**Inflammation and mechanics in OA; exclusive or synergistic entities?**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Jacobsson Lennart (Sweden)</th>
<th>Chair</th>
<th>Myasoedova Elena (United States)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker</td>
<td>Uhlig Till (Norway)</td>
<td>Speaker</td>
<td>Dekker Joost (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>SP0192</td>
<td>Abstract</td>
<td>OP0312</td>
</tr>
<tr>
<td></td>
<td>How to measure comorbidity in the routine clinical setting</td>
<td>How to measure comorbidity in the research setting; a review of available instruments</td>
<td>Impact of comorbidity on common outcomes in rheumatoid arthritis; the importance of adjustment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker</td>
<td>Askling Johan (Sweden)</td>
<td>Speaker</td>
<td>Kobayashi Hitomi (Japan)</td>
</tr>
<tr>
<td>Abstract</td>
<td>OP0313</td>
<td>Abstract</td>
<td>Delgado-Frias E. (Spain)</td>
</tr>
<tr>
<td></td>
<td>EFFECT OF TOCILIZUMAB ON LEFT VENTRICULAR FUNCTION ASSESSED USING A COMPREHENSIVE CARDIAC MAGNETIC RESONANCE APPROACH IN RHEUMATOID ARTHRITIS PATIENTS WITHOUT CARDIAC SYMPTOMS</td>
<td>BODY COMPOSITION AND ABDOMINAL ADIPOSITY IN RHEUMATOID ARTHRITIS PATIENTS: CROSS-SECTIONAL STUDY OF PATIENTS AND CONTROLS</td>
<td></td>
</tr>
</tbody>
</table>

### Basic and Translational Science Session - Room N109/110

**Sugars and lectins in autoimmunity**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Dolhain Radboud (Netherlands)</th>
<th>Chair</th>
<th>Nagy Laszlo (Hungary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker</td>
<td>van Kooij Yvette (Netherlands)</td>
<td>Speaker</td>
<td>Scherer Hans-Ulrich (Netherlands)</td>
</tr>
<tr>
<td>Abstract</td>
<td>SP0195</td>
<td>Abstract</td>
<td>OP0318</td>
</tr>
<tr>
<td></td>
<td>Glycobiology of immune responses</td>
<td>Sugars on ACPA; what can they do?</td>
<td>USE OF AN IN VITRO WHOLE BLOOD DEPLETION ASSAY TO COMPARE THE EFFICACY OF B CELL DEPLETING AGENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS</td>
</tr>
<tr>
<td></td>
<td>CD22 and Siglec-G in B cell function and tolerance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker</td>
<td>Nitschke Lars (Germany)</td>
<td>Abstract</td>
<td>Reddy Venkat (United Kingdom)</td>
</tr>
<tr>
<td>Abstract</td>
<td>OP0319</td>
<td>Abstract</td>
<td>Jacobsen Søren (Denmark)</td>
</tr>
<tr>
<td></td>
<td>GENETICALLY DETERMINED MANNOSE-BINDING LECTIN DEFICIENCY INCREASES RISK OF NEPHRITIS IN DANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Fellows in Training Session - Room N111/112

**Making mentoring effective**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Sivera Francisca (Spain)</th>
<th>Chair</th>
<th>Moltó Anna (Spain)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker</td>
<td>Gay Renate (Switzerland)</td>
<td>Speaker</td>
<td>Gossec Laure (France)</td>
</tr>
<tr>
<td>Abstract</td>
<td>SP0196</td>
<td>Abstract</td>
<td>SP0197</td>
</tr>
<tr>
<td></td>
<td>What to expect from your mentor and how to optimise the mentoring process</td>
<td>View of the mentor</td>
<td></td>
</tr>
</tbody>
</table>
### Health Professionals Session - Room N113/N114

**Vision 2020 - get to know your EULAR Health Professionals; future goals and objectives**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Viet Vieland Thea (Netherlands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Hagen Kåre Birger (Norway)</td>
</tr>
<tr>
<td>Speaker</td>
<td>to be named ()</td>
</tr>
<tr>
<td>Speaker</td>
<td>Oliver Susan (United Kingdom)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Field Robert (United Kingdom)</td>
</tr>
<tr>
<td>Speaker</td>
<td>Ioulianos Costas (Cyprus)</td>
</tr>
</tbody>
</table>

- **Who I am and what I will do as EULAR Vice President HPR to represent the vision for HPs within EULAR**
- **Who I am and what I will do as Standing Committee Chair to represent the vision for HPs within EULAR**
- **An established country member - experience and vision of working with the EULAR Standing Committee for HPR**
- **Becoming a new member - the journey and the vision of working with the EULAR Standing Committee for HPR**

### Practical Skills Session - Room N117

**MRI Advanced 2**

- **Chair** - Ostergaard Mikkel (Denmark)
- **Speaker** - Diekhoff Torsten (Germany)
- **Speaker** - Lambert Robert (Canada)
- **Speaker** - Peterly Charles (United States)
- **Speaker** - Lambert Robert (Canada)

- **MRI for imaging of structural damage of sacroiliac joints – how does it compare to X-ray and CT?**
- **Update on MRI in axial SpA, incl. differential diagnoses and follow-up**
- **Cartilage assessment by MRI in large and small joints in rheumatoid arthritis**
- **Advanced case presentations: interaction and discussion**

### PARE Session - Room N116

**The three musketeers – Equity for all: Availability, affordability and acceptability of arthritis health care in Europe**

- **Chair** - Chichikj Dragan (Macedonia, The former Yugoslavia Republic of)
- **Chair** - Skingle Diana (United Kingdom)
- **Speaker** - de Wit Maarten (Netherlands)
- **Speaker** - Woof Anthony (United Kingdom)
- **Speaker** - Sokka Tuulikki (Finland)
- **Speaker** - Koutsogianni Katerina (Greece)
- **Abstract** - Aldrin Kicki (Sweden)

- **How patients can contribute to and benefit from HTA (Health Technology Assessment) to improve equity in Europe**
- **Facilitators of RMD health care in Europe: How the EUMUSC project provides data**
- **Quality of life of people with RMDs around Europe. Can it be improved?**
- **Barriers and opportunities for patient organisations in economically disadvantaged European countries**
- **?BE WELCOME?, A PROJECT ABOUT THE MEDICAL CONSULTATION.**

### Saturday 15.06.2013 13:45 - 14:45

**Highlight Session - Hall 8**

**Highlight Session Clinical**

- **Chair** - Buckley Chris (United Kingdom)
- **Chair** - Buch Maya (United Kingdom)
- **Speaker** - Müller-Ladner Ulf (Germany)
- **Speaker** - Gottenberg Jacques-Eric (France)

- **Highlights of the Basic and Translational sessions**
- **Highlights of the Clinical sessions**
### Highlight Session - Room N113/114

#### Highlight Session Health Professionals

- **Chair**: Boström Carina (Sweden)
- **Chair**: Betteridge Kate (United Kingdom)
- **Chair**: McInnes Iain (United Kingdom)
- **Speaker**: McInnes Iain (United Kingdom)
  - 3 key take home messages from the scientific programme
- **Speaker**: Betteridge Kate (United Kingdom)
  - 3 key take home messages from the PARE programme
- **Speaker**: Boström Carina (Sweden)
  - 3 key take home messages from the Health Professional programme

### Highlight Session - Room N116

#### Highlight session PARE

- **Chair**: Batziou Maria (Greece)
- **Chair**: Betteridge Neil (United Kingdom)
- **Speaker**: de la Torre-Aboki Jenny (Spain)
  - Highlights from the Health Professional programme
- **Speaker**: Burmester Gerd Rüdiger (Germany)
  - Highlights from the scientific programme
- **Speaker**: Betteridge Neil (United Kingdom)
  - Moderated discussion with and feedback from the audience